

Subject Index—Volume 78

- No. 1, July 1, pp. 1-194
 No. 2, July 15, pp. 195-382
 No. 3, August 1, pp. 383-578
 No. 3, August 1, Supplement, pp. 579-694
 No. 4, August 15, pp. 695-940
 No. 5, September 1, pp. 941-1148
 No. 6, September 15, pp. 1149-1358
 No. 7, October 1, pp. 1359-1524
 No. 7, October 1, Supplement, pp. 1525-1638
 No. 8, October 15, pp. 1639-1846
 No. 9, November 1, pp. 1847-2038
 No. 10, November 15, pp. 2039-2260
 No. 11, December 1, pp. 2261-2454
 No. 12, December 15, pp. 2455-2652
- A**
 Acquired immunodeficiency syndrome, lymphoma in centromeric instability of chromosome 1 in, 1142 (letter)
 chemotherapy for, 517
 Acute leukemia. *See* Leukemia
 Acute polyneuropathy, cytosine and, 1899
 Adenocarcinoma. *See* specific sites and types
 Adenohypophyseal neoplasms, WHO classification of, 502
 Adenomatous polyps, colorectal, calcium and vitamin supplements and, 723
 Adjustment disorder, in terminal cancer, 1131
 Adoptive immunotherapy, for nonsmall cell lung cancer, 195 (editorial), 244
 Adrenocortical cancer, mitotane for, 1520
 Adult T-cell leukemia/lymphoma
 gastric lesions in, 396
 primary malignant tumors in, 1119
 African Americans
 breast cancer prognosis in, 1241
 graft-versus-host disease in, 1492
 intention to undergo prostate cancer screening in, 471
 pediatric cancer incidence trends in, 532
 prostate cancer screening use and, 1942
 Age
 breast cancer and
 National Cancer Data Base report on, 1838
 prognosis and, 1517 (letter)
 colon cancer and, 1666
 AIDS, lymphoma in
 centromeric instability of chromosome 1 in, 1142 (letter)
 chemotherapy for, 517
 Alfred P. Sloan Prize lecture, 558
 Alpha-fetoprotein
 in hepatocellular cancer, prognosis and, 2094
 in hepatocellular cancer screening, in cirrhosis, 977
 Alveolar rhabdomyosarcoma, minimal disease detection in, by reverse transcriptase-PCR, 1320
 American Cancer Society, National Cancer Institute and, 2609
 American Joint Committee on Cancer Staging, National Cancer Data Base report on, 1498
 5-Aminolevulinic acid, with photodynamic therapy, for oral premalignant and malignant lesions, 1374
 Analgesia
 opioid rotation in, 852
 in pancreatic cancer, 605, 639
 Anaplastic large cell lymphoma, Ki-1-positive, in Asia, 1805
 Anemia, erythropoietin for, with/without chemotherapy, 1144 (letter)
 Angiogenesis, prognosis and
 in colorectal cancer, 226
 in lung cancer, 409
 in pancreatic cancer, 680
 in prostate cancer, 345
 Angiomyxoma, aggressive, clinicopathology of, 79
 Angiosarcoma, pericardial, after mediastinal irradiation for seminoma, 912
 Anterior pituitary tumors, WHO classification of, 502
 Antiangiogenic strategies, for pancreatic cancer, 680
 Antibodies, monoclonal. *See* Monoclonal antibodies
 Anti-carcinoembryonic antigen murine monoclonal antibody, MN-14 F(ab)₂, tumor targeting with, 157
 Antidepressants, in pancreatic cancer, 615
 Antiemetics
 granisetron, dosage of, 144
 in head and neck cancer, 2450 (letter)
 placebo trials of, 2193
 Antigen(s)
 CA 15-3, in pleural fluid, 736
 CA 19-9
 in pancreatic cancer, 57
 in pancreatic cystic tumors, 237
 in pleural fluid, 736
 CA 72-4
 in pancreatic cystic tumors, 237
 in pleural fluid, 736

- CA 125
 in ovarian tumors, 118
 transforming growth factor- α and, 1049
 in pancreatic cancer, 57
 carcinoembryonic
 in breast cancer, collection of by absorbent disk applied to nipple, 1229
 in pancreatic cancer, 57
 in pleural fluid, 736
 free-prostate specific, 809
 Ki-67
 in endometrial cancer, prognosis and, 1942
 in Epstein-Barr virus-associated salivary gland cancer, 695
 in oligodendrogliomas, prognosis and, 1107
 in situ vs. invasive extrahepatic biliary cancer, 1881
 in ulcerative colitis, 2307
 proliferating cell nuclear
 in bladder cancer, 1762
 in endometrial cancer, prognosis and, 1942
 in esophageal dysplasia, 1514 (letter)
 in situ vs. invasive extrahepatic biliary cancer, 1881
 proliferation-associated nuclear antigen p105, in renal cell carcinoma, 819
 prostate specific, prognosis and, 341
 prostate specific membrane, 809
 sialosyl-Tn, in gastric cancer, prognosis and, 171 (letter)
 sialyl Lewis X, in colorectal cancer, hepatic metastasis and, 1179
 tissue polypeptide, in ovarian tumors, transforming growth factor- α and, 1049
- Anxiety
 in cancer patients, 615
 in terminal cancer, 1131
- Aortic nodal metastases, in epithelial ovarian cancer, 803
- Apoptosis, spontaneous, in gallbladder cancer, 2101
- Ara-C
 acute polyneuropathy and, 1899
 ocular toxicity of, 1359
- Arthroplasty, histiocytic lymphadenopathy after, 834
- Asia. *See also specific countries*
 Ki-1 anaplastic large cell lymphoma in, 1805
- Aspiration biopsy, in breast cancer, vs. core needle biopsy, 773
- Astrocytoma
 phosphotyrosine and Neu/ErB-2 in, 1272
 tumor suppressor gene alterations in, 287
- B**
- Basal cell adenocarcinoma, of salivary glands, 2471
- Base of tongue cancer, radiation therapy for, 948
- bcl-2 protooncogene, in gallbladder cancer, spontaneous apoptosis and, 2101
- Benign lymphoepithelial lesions, vs. Epstein-Barr virus-associated salivary gland cancer, 695
- Betel quid chewing, head and neck cancer and, lymph node density and drug response in, 1972
- Bicalutamide, vs. flutamide, for prostate cancer, 2164
- Biliary cancer, in situ vs. invasive, proliferating cell nuclear antigen and Ki-67 antigen in, 1881
- Biopsy
 core needle
 of breast
 vs. fine-needle aspiration cytology, 773
 of radiologically detected lesions, 2340
 in prostate cancer, 350, 366, 376
 stereotactic, PET-guided, of glioma, 1098
- Birth defects, in offspring of acute lymphoblastic leukemia survivors, 169
- Bladder cancer
 cystectomy vs. conservative therapy for, quality of life after, 1089
 matrix metalloproteinases-2 and 3, recurrence and, 2379
 National Cancer Data Base report on, 1498
 proliferating cell nuclear antigen, p53, nm23 and DNA content in, 1762
- Bleomycin
 for AIDS-related lymphoma, 517
 with tetracycline, for malignant pleural effusions, 2498
- Bone, desmoplastic fibroma of, 1011
- Bone alkaline phosphatase, in prostate cancer staging, 2374
- Bone marrow transplantation
 graft-versus-host disease and, race and, 1492
 ocular complications in, 1359
- Bone metastasis, intertrabecular patterns in, 1388
- Brachytherapy, for base of tongue cancer, 948
- Brain edema, in meningioma, MIB-1 staining index for, 133
- Brain metastases
 from colorectal cancer, 711
 histology, multiplicity, surgery and survival with, 1781
 single, surgery with radiotherapy for, 1470
- Brain tumors. *See also specific types*
 astrocytoma, phosphotyrosine and Neu/ErB-2 in, 1272
 germ cell, histology of, prognosis and, 2514
 glioma, histopathology of, regional glucose metabolism and, 1098
 gliomatosis cerebri, radiation therapy for, 1789
 pineal, histology of, prognosis and, 2514
 topotecan for, 527
 xanthoastrocytoma, with cortical dysplasia and neuronal tumors, 2551
- BRCA2, in breast cancer, 1921
- Breast biopsy, core needle
 after radiological lesion detection, 2340
 vs. fine-needle aspiration cytology, 773
- Breast cancer
 age-related prognosis in, 1517 (letter)
 BRCA2 in, 1921
 breast-conserving surgery for, pathologic margins and recurrence risk in, 1921
 carcinoembryonic antigen in, collection of by absorbent disk applied to nipple, 1229
 chemotherapy for, MRI evaluation after, 91

- combined melanoma and ductal carcinoma, 2515
 core needle biopsy for, vs. fine-needle aspiration cytology, 773
 core needle biopsy in, of radiologically detected lesions, 2340
 detection of with radiolabeled monoclonal antibodies, 2334
 diet and exercise in, improved prognosis with, 2465
 ductal in situ, prognostic index for, 1138 (letter)
 early
 conservative therapy for, tumor grade in, outcome and, 1426
 radiation therapy for, 1035
 estrogen receptor determinations in, by biochemical ligand-binding assay vs. immunohistochemical staining with monoclonal antibody ER1D5, 764
 fadrozole hydrochloride for, 789
 interval, histopathology and growth rate of, 1220
 invasive, in situ carcinoma-associated immunity in, 778
 lobular in situ, pathologic findings in, from National Surgical Adjuvant Breast Project Protocol B-17, 1403
 localized, estrogen replacement therapy after, 1043
 mammography for, for women 40-49 years, 572 (letter)
 management of, in elderly, 101
 metastatic, serum interleukin-6 in, medroxyprogesterone acetate reduction of, 2346
 National Cancer Data Base report on, for age-related characteristics and outcome, 1838
 nonpalpable, age-related differences in, 1432
 with occult nodal metastasis, histology of, 1235
 prognosis in, ethnicity and, 1241
 retinoblastoma gene in, 1921
 risk of
 atypical hyperplasia in papillomas and, 258
 lobular neoplasia and, 1024
 screening for. *See* Mammography
 serial serum *c-erbB-2* in, 267
 stage I and II, breast preservation in, 1722
 tamoxifen, etoposide, mitoxantrone and cisplatin for, 1906
 13q deletion mapping in, 1921
 in young women, family history and survival in, 1417
 Breast lesions, radiologically detected, core needle biopsy of, 2340
 Breast papilloma, with atypical hyperplasia, cancer risk and, 258
 Breast self-examination, in elderly, 101
 Burkitt's disease, revised European-American classification for, 4
 Busulfan, ocular toxicity of, 1359
 BZLF-1, in nasopharyngeal cancer, 24
- C**
 CA 15-3, in pleural fluid, 736
 CA 19-9
 in pancreatic cancer, 57
 in pancreatic cystic tumors, 237
 in pleural fluid, 736
 CA 72-4
 in pancreatic cystic tumors, 237
 in pleural fluid, 736
 CA 125
 in ovarian tumors, 118
 transforming growth factor- α and, 1049
 in pancreatic cancer, 57
 Calcium, supplemental, colorectal adenomatous polyps and, 723
 Cancer
 declining mortality in, 2045
 high-risk populations for, interdisciplinary approach to, 548 (Mott Prize lecture)
 pediatric. *See* Children; Pediatric cancer
 prevention of, hormones, vitamins, and growth factors in, 2264
 survival in, global variations in, 2461
 Cancer patients, psychiatric disorders in, 615
 Cancer registries, survival monitoring in, 2004
 Carboplatin
 for nonsmall cell lung cancer, 998, 1701
 ocular toxicity of, 1359
 Carcinoembryonic antigen
 in breast cancer, collection of by absorbent disk applied to nipple, 1229
 in pancreatic cancer, 57
 in pleural fluid, 736
 Carcinoid tumors, peritoneal carcinomatosis in, 1686
 Carmustine, ocular toxicity of, 1359
 Cathepsin D, in cervical cancer, prognosis and, 433
 Catheter, Groshong, complications with, 1308
 Catheterization, central, in thrombocytopenia, 2025
 Cd11a expression on CD8+ cells, suppression of in lymph nodes, in gastrointestinal cancer, 1677
 CD34 expression, multidrug resistance and, in ovarian cancer cell line, 2427
 CD44
 in prostate cancer, 1461
 in seminoma, 2443 (letter)
 Celiac nerve block, for pancreatic cancer, 605
 Central line placement complications, in thrombocytopenia, 2025
c-erbB-2
 in breast cancer, 267
 in cervical cancer, prognosis and, 433
 Cerebral. *See also* Brain
 Cerebral edema, in meningioma, MIB-1 staining index for, 133
 Cerebral metastasis
 from colorectal cancer, long-term survival with, 711
 histology, multiplicity, surgery and survival with, 1781
 single, surgery with radiotherapy for, 1470
 Cervical cancer
 cathepsin D, epidermal growth factor receptor, and *c-erbB-2* in, prognosis and, 433
 clinical features of, human papillomavirus type and, 1935

- early, surgically defined prognostic parameters in, 1438
 IgG in, 511
 radiation-treated, high-resolution MRI of, 2535
 screening for, neural network technology in, 112
 stage III, radical hysterectomy with lymphadenectomy for, 2359
- Charles F. Kettering Prize lecture, 542
- Charles S. Mott Prize lectures, 548, 553
- Chemical splachnicectomy, for pancreatic cancer, 605
- Chemoembolization, hepatic, PET with F-18-fluoro-deoxyglucose in, 2216
- Chemofiltration, 1125
- Chemosenitivity and chemoresistance assays, 2031 (letter)
- Chemotherapy. *See also specific drugs*
 for advanced pancreatic and gallbladder cancer, 1300
 for AIDS-related lymphoma, 517
 bolus vs. infusion, costs of, 294, 300
 for breast cancer, 789, 1906
 in elderly, 101
 MRI evaluation after, 91
 for colorectal cancer metastatic to liver, 1639
 drug resistance in, CD34 expression and, in ovarian cancer cell line, 2427
 with erythropoietin, for anemia, 1144 (letter)
 for esophageal cancer, 30, 1851, 2070
 with radiotherapy, 1646
 for Ewing's sarcoma, 70, 901
 for gastric cancer, 211
 gastroduodenal mucosal injury in, misoprostol and omeprazole for, 1477
 for head and neck cancer, response to, lymph node density and, 1972
 hepatitis and, in hepatitis B virus carriers with hematologic cancers, 2210
 late effects of, birth defects in offspring as, 169
 for lymph node metastases, 2199
 for myelodysplastic syndromes, 422
 for nasopharyngeal cancer, 566 (letter)
 for nonsmall cell lung cancer, 63, 998
 response to, glutathione S-transferase- π and, 416
 ocular toxicity of, 1359
 for osteosarcoma, 741
 for ovarian cancer
 CA 125 as response marker in, 118
 platinum vs. nonplatinum-based, 2157
 for pancreatic cancer, 580, 592, 633, 654, 664, 674, 688
 for pediatric CNS tumors, 527
 for pulmonary blastoma, 569
 for rectal cancer, 217
 regional
 for regionally advanced tumors, 941 (editorial)
 vs. systemic, for colorectal cancer metastatic to liver, 1639
 regional perfusion with hemofiltration with, 1125
 for testicular cancer, response to, with teratoma, 480
 for transitional cell carcinoma, 1775
- Children. *See also Neuroblastoma; Pediatric cancer and specific cancers of childhood, e.g., Leukemia*
 brain tumors in, topotecan for, 527
 Hodgkin's disease survivors, irreversible male gonadal damage in, 2020
 quality of life for, research in, 1333
 soft tissue sarcoma in, familial cancer predisposition and, 1483
- China, Ki-1 anaplastic large cell lymphoma in, 1805
- Chlorambucil, ocular toxicity of, 1359
- Cholangiocarcinoma, with hepatocellular carcinoma, surgery for, 1671
- Chondrosarcoma, pelvic, prognostic factors for, 745
- Cigarette smokers, former, lung cancer in, 1004
- Circulating tumor cells, PCR detection of, 1 (editorial), 10
- Cirrhosis, hepatocellular carcinoma screening in, 977
- Cirrhotic hepatocytes, DNA content of, hepatocellular cancer prognosis and, 1195
- Cisplatin
 antiemetics for, placebo trials of, 2193
 for breast cancer, 1906
 for clear cell ovarian cancer, 2157
 for esophageal cancer, 30, 2070
 with radiotherapy, 1646
 for gynecologic cancer, 1798
 for head and neck cancer, response to, lymph node density and, 1972
 for nasopharyngeal cancer, 566 (letter)
 for nonsmall cell lung cancer, 63, 998
 ototoxicity and, 1798
- Clear cell carcinoma
 endometrial, 1740
 ovarian, platinum vs. nonplatinum-based chemotherapy for, 2157
- Clinical trials
 of antiemetics, 2193, 2450 (letter)
 in pancreatic cancer, endpoints for, 627
- Cold virus, cancer and, 558 (Sloan Prized lecture)
- Colectomy
 prophylactic, for carriers in hereditary nonpolyposis colorectal cancer, 199
 for rectal cancer, 1847 (editorial)
- Colitis
 chronic, dysplasia in, significance and detection of, 2261 (editorial)
 ulcerative, DNA hypomethylation and proliferation in rectal mucosa in, cancer risk and, 2300
- Colorectal adenomatous polyps, calcium and vitamin supplements and, 723
- Colorectal cancer. *See also Rectal cancer*
 advanced
 ¹³¹I anti-CEA monoclonal antibody and hyperthermia in, 1861
 doxifluridine plus levo-leucovorin for, 2087
 age, sex and site distribution of, 1666
 angiogenesis in, prognosis and, 226
 brain metastases from, long-term survival with, 711
 cytokine microenvironment of, 1168

5-fluorouracil and leucovorin for, hypocalcemia and, 1794
 hepatic metastasis in
 focal dedifferentiation and sialyl Lewis X antigen and, 1179
 regional vs. systemic chemotherapy for, 1639
 venous invasion in, 2313
 hereditary nonpolyposis, 1149
 carriers of, prophylactic colectomy for, 199
 incidence of, in Japan, 1187
 lanreotide for, 35
 National Cancer Data Base report, 918
 occult blood testing in, haptoglobin detection in, 48
 S-phase fraction and tumor aneuploidy in, in young patients, 1857
 sporadic proximal, transforming growth factor- β type II receptor gene mutations and, 2478
 sulfatides in, nodal metastasis and, 43
 treated with resection only, prognostic factors for, 403
 ulcerative colitis and
 cell proliferation in neoplastic vs. nonneoplastic lesions in, 2307
 DNA hypomethylation and proliferation as risk factors for, 2300
 Common cold virus, cancer and, 558 (Sloan Prized lecture)
 Computer image analysis, for pigmented skin lesions, 252
 Congenital anomalies, in offspring of childhood acute lymphoblastic leukemia, 169
 Congenital hypertrophy of retinal pigment epithelium, in familial adenomatous polyposis, 2400
 Core needle biopsy
 of breast lesions
 after radiological detection, 2340
 vs. fine-needle aspiration cytology, 773
 in prostate cancer, 350, 366, 376
 Corticosteroids, ocular toxicity of, 1359
 Craniotomy, for brain metastasis, 1781
 Cyclin D1
 in hypopharyngeal cancer, 390
 in oral verrucous carcinoma, 17
 p53 and, coabnormal expression of, in endometrial cancer, 1248
 Cyclophosphamide
 for AIDS-related lymphoma, 517
 for Ewing's sarcoma, 70, 901
 ocular toxicity of, 1359
 Cyclosporine, ocular toxicity of, 1359
 Cystectomy, vs. conservative therapy, quality of life after, 1089
 Cystic pancreatic tumors, tumor markers and cyst fluid analysis in, 237
 Cytarabine, for myelodysplastic syndromes, 422
 Cytokines, in colorectal cancer, 1168
 Cytosine arabinoside
 acute polyneuropathy and, 1899
 ocular toxicity of, 1359

D

D44, in vulvar cancer, prognosis and, 273
 Deafness. *See* Ototoxicity
 Deep vein thrombosis
 in clear cell ovarian carcinoma treated with platinum-based chemotherapy, 2157
 Goshong catheter-related, 1308
 Delirium, in terminal cancer, 1131
 Dementia, in terminal cancer, 1131
 Deoxycytosine, ocular toxicity of, 1359
 Depression
 in cancer patients, 615
 in pancreatic cancer, 615
 in terminal cancer, 1131
 Desmoid fibromatosis, of sinonasal tract and nasopharynx, 2572
 Desmoplastic fibroma of bone, 1011
 Desmoplastic melanoma, of oral mucosa, 383
 Desmoplastic small cell tumor, intraabdominal, 845
 Desmosomal proteins, in uterine cancer, cellular differentiation and, 461
 Des- γ -carboxy prothrombin, in hepatocellular cancer, prognosis and, 2094
 Dexamethasone, for AIDS-related lymphoma, 517
 Diagnostic pathology, molecular techniques in, 1 (editorial)
 Diet
 in breast cancer, improved prognosis with, 2465
 colorectal adenomatous polyps and, 723
 colorectal cancer and, in Japan, 1187
 Digestive endocrine tumors, peritoneal carcinomatosis in, 1686
 DNA content
 in bladder cancer, 1762
 of borderline malignant ovarian tumors, 794
 of cirrhotic hepatocytes, hepatocellular cancer prognosis and, 1195
 of desmoplastic fibroma of bone, 1011
 in prostate cancer, 1748
 in renal cell carcinoma, 819
 DNA hypomethylation, in ulcerative colitis, cancer risk and, 2300
 DNA index, in glial tumors, tumor grade and prognosis and, 881
 DNA topoisomerase II α , in small cell vs. nonsmall cell lung cancer, 729
 Doxifluridine, with levo-leucovorin, for advanced colorectal cancer, 2087
 Doxorubicin
 for AIDS-related lymphoma, 517
 for Ewing's sarcoma, 70, 901
 for gastric cancer, 1988
 ocular toxicity of, 1359
 Drug resistance, CD34 expression and, in ovarian cancer cell line, 2427
 Drugs. *See* Chemotherapy
 Ductal carcinoma in situ of breast, prognostic index for, 1138 (letter)

- Duodenal cancer, periampullary, 568 (letter)
- Duodenal obstruction, in pancreatic cancer, management of, 605
- Dyspnea, in advanced cancer, management and significance of, 1314

E

- E-cadherin, in gallbladder cancer, spontaneous apoptosis and, 2101
- Eccrine porocarcinoma, of heel, 751
- Economic factors, in mammography use, 1912
- Edema, cerebral, in meningioma, MIB-1 staining index for, 133
- Elderly, breast cancer in, management of, 101
- Embolism, in clear cell ovarian carcinoma treated with platinum-based chemotherapy, 2157
- Endometrial cancer
 - clear cell, 1740
 - coabnormal expression of cyclin D1 and p53 in, 1248
 - interferon- β induction of progesterone receptors in, 448
 - proliferation markers in, prognosis and, 1942
 - vascular invasion in, prognosis and, 1447
 - vascular permeability factor in, 458
- Endorectal coil magnetic resonance imaging, of radiation-treated cervical cancer, 2535
- Epidermal growth factor receptor
 - in cervical cancer, prognosis and, 433
 - in head and neck cancer, 1284
 - tumor marker secretion from ovarian tumors and, 1049
- Epirubicin, for nonsmall cell lung cancer, 63
- Epithelioid hemangioendothelioma, of liver, 2318
- Epstein-Barr virus-associated salivary gland cancer, 695
- Epstein-Barr virus-encoded RNA, in nasopharyngeal cancer, 24
- Erratum, 578
- Erythrocyte polyamine spermine levels, in hormone refractory prostate cancer, 1055
- Erythropoietin, for anemia, with/without chemotherapy, 1144 (letter)
- Esophageal cancer
 - cisplatin and etoposide for, 2070
 - 5-fluorouracil, interferon- α -2b and cisplatin for, 30
 - human papillomavirus in, 704
 - locoregional, multimodality treatment of, 1851
 - National Cancer Data Base report on, 1820
 - radiochemotherapy for, with etoposide and cisplatin, 1646
- Esophageal dysplasia, proliferating cell nuclear antigen in, 1514 (letter)
- Esophagus, gastrointestinal autonomic nerve tumor of, 651
- Estrogen receptor determinations, in breast cancer, by biochemical ligand-binding assay vs. immunohistochemical staining with monoclonal antibody ER1D5, 764
- Estrogen replacement therapy, after localized breast cancer, 1043
- Ethnicity. *See* Race

Etoposide

- with autologous blood progenitor cell rescue, for myeloma, 2502
 - for breast cancer, 1906
 - for esophageal cancer, 2070
 - with radiotherapy, 1646
 - for Ewing's sarcoma, 901
 - for gastric cancer, with tegafur plus uracil and leucovorin modulation, 211
 - for myelodysplastic syndromes, 422
 - for nonsmall cell lung cancer, 998
- Ewing's sarcoma
- chemotherapy for, 901
 - femoral, treatment of, 70
 - surgical margins for, prognosis and, 892
- Exercise, in breast cancer, improved prognosis with, 2465

F

- Fadrozole hypochloride, for breast cancer, 789
- Familial adenomatous polyposis
 - congenital hypertrophy of retinal pigment epithelium in, 2400
 - rectal polyposis in, indomethacin suppositories for, 1660
- Familial cancer predisposition, pediatric soft tissue sarcoma and, 1483
- Fat, dietary
 - colorectal adenomatous polyps and, 723
 - colorectal cancer and, in Japan, 1187
 - reduction of, improved breast cancer prognosis with, 2465
- Fecal occult blood testing, for colorectal cancer, haptoglobin detection in, 48
- Femoral Ewing's sarcoma, treatment of, 70
- Fertility
 - in pediatric Hodgkin's disease survivors, 2020
 - in Wilms' tumor survivors, 887
- α -Fetoprotein
 - in hepatocellular carcinoma, prognosis and, 2094
 - in hepatocellular carcinoma screening, in cirrhosis, 977
- Fibroma, desmoplastic, of bone, 1011
- Fine-needle aspiration cytology, in breast cancer, vs. core needle biopsy, 773
- Flap, gracilis myocutaneous, in vaginal reconstruction, sexual function after, 2229
- Flow cytometry. *See* DNA content
- 5-Fluorouracil
 - for advanced pancreatic and gallbladder cancer, 1300
 - for esophageal cancer, 30, 1851
 - for gastric cancer, 1988
 - with leucovorin
 - for gastrointestinal cancer, hypocalcemia and, 1794
 - for metastatic gastric/pancreatic cancer, 1888
 - for nasopharyngeal cancer, 566 (letter)
 - ocular toxicity of, 1359
 - for rectal cancer, with radiotherapy, 217
 - for renal cell carcinoma, 1085

Flutamide, vs. bicalutamide, for prostate cancer, 2164
 Fotemustine, toxicity of, 1980
 Free-prostate specific antigen, 809

G

Gallbladder cancer
 advanced, chemotherapy for, 1300
 risk factors for, 1515
 in situ vs. invasive, proliferating cell nuclear antigen and Ki-67 antigen in, 1881
 spontaneous apoptosis in, 2101
 Gastric cancer
 etoposide plus tegafur for, with uracil and leucovorin modulation, 211
 5-fluorouracil and leucovorin for, 1888
 hypocalcemia and, 1794
 modified dose intensive 5-fluorouracil, doxorubicin, methotrexate and leucovorin for, 1988
 multiple early, clinicohistopathology of, 2078
 sialosyl-Tn antigen in, prognosis and, 171 (letter)
 in stump vs. intact stomach, 2288
 T antigen in, prognosis and, 2448 (letter)
 Gastric lesions, in adult T-cell leukemia/lymphoma, 396
 Gastrinoma, peritoneal carcinomatosis in, 1686
 Gastrointestinal autonomic nerve tumor of esophagus, 651
 Gastrointestinal cancer. *See also specific sites and types*
 Cd11a expression on CD8+ cells in, suppression of in lymph nodes, 1677
 Gemcitabine, for pancreatic cancer, 633
 Gender
 colon cancer and, 1666
 weight loss in nonsmall cell lung cancer and, 2119
 Gentiourinary anomalies, in Wilms' tumor survivors, 887
 Germ cell tumors, intracranial, histology of, prognosis and, 2514
 Glial tumors, DNA index in, tumor grade and prognosis and, 881
 Glioma, histopathology of, regional glucose metabolism and, 1098
 Gliomatosis cerebri, radiation therapy for, 1789
 Glottic cancer
 radiation therapy for, 183 (letter)
 radiation-treated, p53 in, prognosis and, 1693
 Glucose metabolism, glioma histopathology and, 1098, 1099
 Glutathione S-transferase- π , in nonsmall cell lung cancer, chemotherapy response and, 416
 Gonadal damage, in male pediatric Hodgkin's disease survivors, 2020
 Gracilis myocutaneous flap, in vaginal reconstruction, sexual function after, 2229
 Graft-versus-host disease, race and, 1492
 Granisetron
 for cisplatin-associated emesis, 2193
 in head and neck cancer, 2450 (letter)
 dosage of, 144
 Granulocyte-macrophage colony stimulating factors, in colon cancer, 1168

Groshong catheter, complications with, 1308
 Growth factors, in cancer treatment and prevention, 2264
 Gynecologic cancer. *See also specific sites and types*
 cisplatin for, ototoxicity and, 1798
 IgG in, 511

H

Haptoglobin detection, in colorectal cancer, 48
 Head and neck cancer
 lymph node density in, cisplatin-based chemotherapy response and, 1972
 radioresistance in, p53 status and, 991
 transforming growth factor- α and epidermal growth factor receptor in, 1284
 Hearing loss. *See* Ototoxicity
 Heel, eccrine porocarcinoma of, 751
 Hemangioendothelioma, epithelioid, of liver, 2318
 Hematologic cancer
 in hepatitis B virus carriers, chemotherapy-related hepatitis in, 2210
 minimum residual disease in, PCR detection of, 10
 Hepatic chemoembolization, PET with F-18-fluorodeoxyglucose in evaluation of, 2216
 Hepatic epithelioid hemangioendothelioma, 2318
 Hepatic metastasis, in colorectal cancer
 focal dedifferentiation and sialyl Lewis X antigen and, 1179
 regional vs. systemic chemotherapy for, 1639
 venous invasion and, 2313
 Hepaticojunostomy, for pancreatic cancer, 605
 Hepatic portal lymphoma, 2011
 Hepatitis, chemotherapy-related, in hepatitis B carriers with hematologic cancers, 2210
 Hepatobiliary presentation, of lymphoma, 2011
 Hepatocellular cancer, des-y-carboxy prothrombin and α -fetoprotein for, 2094
 Hepatocellular carcinoma
 chemofiltration for, 1125
 with cholangiocarcinoma, surgery for, 1671
 cirrhotic liver cells in, DNA flow cytometry of, 1195
 differential diagnosis of, telomerase for, 232
 screening for, in cirrhosis, 977
 Hepatotoxicity, of fotemustine, 1980
 Hereditary cancer susceptibility (Mott Prize lecture), 553
 Hereditary nonpolyposis colorectal cancer, 1149
 carriers of, prophylactic colectomy for, 199
 Hip arthroplasty, histiocytic lymphadenopathy after, 834
 HIV, lymphoma in, centromeric instability of chromosome 1 in, lymphoma in, centromeric instability of chromosome 1 in, 1142 (letter)
 HLA-DQB1*0301, in melanoma, recurrence and, 758
 HMB-45, in metastatic uveal melanoma, 1967
 Hodgkin's disease
 first relapse in, prognostic factors after, 1293
 pediatric, male survivors of, irreversible gonadal damage in, 2020
 pregnancy-associated, 304
 revised European-American classification for, 4

- Hormone replacement therapy, after localized breast cancer, 1043
- Hormones, in cancer treatment and prevention, 2264
- Hospital reporting, National Cancer Data Base report on, 1820
- Human chorionic gonadotropin, in cell lines, 184 (letter)
- β -Human chorionic gonadotropin, metastasis and, 2388
- Human immunodeficiency virus, lymphoma in centromeric instability of chromosome 1 in, 1142 (letter)
- chemotherapy for, 517
- Human papillomavirus
- in esophageal cancer, 704
- type of, cervical cancer clinical behavior and, 1935
- Hydromorphone, for cancer pain, dose ratios with methadone in, 852
- Hydroxyurea, for advanced pancreatic and gallbladder cancer, 1300
- Hypercalcemia, parathyroid hormone-related protein and, in lung cancer, 1384
- Hyperthermia, for advanced colorectal cancer, 1861
- Hypocalcemia, 5-fluorouracil and leucovorin and, 1794
- Hypopharyngeal cancer, cyclin D1 overexpression in, 390
- Hysterectomy, radical, with lymphadenectomy, in stage III cervical cancer, 2359

I

- ¹³¹I anti-CEA monoclonal antibody, for advanced colorectal cancer, 1861
- Ifosfamide
- for Ewing's sarcoma, 901
- ocular toxicity of, 1359
- IgG, in gynecologic cancer, 511
- Immunotherapy, for nonsmall cell lung cancer, 195 (editorial), 244
- Incontinence, urinary, pelvic autonomic nerve preservation and, in rectal cancer, 1871
- Indomethacin suppositories, for rectal polyposis, 1660
- Infertility
- in pediatric Hodgkin's disease survivors, 2020
- in Wilms' tumor survivors, 887
- Inflammatory bowel disease. *See* Ulcerative colitis
- In situ hybridization, in nasopharyngeal cancer, 24
- Interferon, for melanoma, 944
- Interferon- α
- ocular toxicity of, 1359
- for renal cell carcinoma, 1085
- Interferon- α -2b
- for esophageal cancer, 30
- for medullary thyroid cancer, 1114
- Interferon- β , progesterone receptor induction by, in endometrial adenocarcinoma, 448
- Interferon-gamma, in colon cancer, 1168
- Interleukin(s), in colon cancer, 1168
- Interleukin-2, for nonsmall cell lung cancer, 195 (editorial), 244
- Interleukin-6, in breast cancer, medroxyprogesterone acetate reduction of, 2346

- International Consultation on Prostatic Intraepithelial Neoplasia and Pathological Staging of Prostatic Carcinoma, 320-381
- conference summary for, 324
- Intraabdominal desmoplastic small cell tumor, 845
- Intrapulmonary meningiomas, primary, 2328
- Intravenous immunoglobulin, for ovarian cancer with paraneoplastic cerebellar degeneration, 2153
- ¹³¹Iodine, for pulmonary metastases, from papillary thyroid cancer, 2184

J

- Japan
- colorectal cancer incidence in, 1187
- Epstein-Barr virus-associated salivary gland cancer in, 695
- Jaundice, in pancreatic cancer, management of, 605

K

- Kettering Prize lecture, 542
- Ki-1 anaplastic large cell lymphoma, in Asia, 1805
- Ki-67
- in endometrial cancer, prognosis and, 1942
- in Epstein-Barr virus-associated salivary gland cancer, 695
- in oligodendrogliomas, prognosis and, 1107
- in in situ vs. invasive extrahepatic biliary cancer, 1881
- in ulcerative colitis, 2307

L

- Lanreotide, for colorectal cancer, 35
- Large cell lymphoma, Ki-1 anaplastic, in Asia, 1805
- Laryngeal cancer, radioresistance in, p53 status and, 991
- Latent membrane protein, in nasopharyngeal cancer, 24
- Leucovorin
- with 5-fluorouracil
- for gastrointestinal cancer, hypocalcemia and, 1794
- for metastatic gastric/pancreatic cancer, 1888
- for gastric cancer, 1988
- for nasopharyngeal cancer, 566 (letter)
- Leukemia. *See also* Adult T-cell leukemia/lymphoma
- acute lymphoblastic
- adult survivors of, birth defects in offspring of, 169
- overt testicular disease at diagnosis in, prognosis and, 2437
- cytosine for, acute polyneuropathy and, 1899
- extramedullary acute promyelocytic, 2510
- renal cell carcinoma and, 2421
- Levofolinic acid, for advanced pancreatic and gallbladder cancer, 1300
- Levo-leucovorin, with doxifluridine, for advanced colorectal cancer, 2087
- Literacy, mammography use and, 1912
- Liver. *See under* Hepatic; Hepatocellular
- Lobular neoplasia, breast cancer risk and, 1024
- Lonidamine, for nonsmall cell lung cancer, 63
- Lung. *See also under* Pulmonary
- malignant fibrous histiocytoma of, 2492

- metastasis to
 - micronodular, from papillary thyroid cancer, 131-I for, 2184
 - from papillary thyroid cancer, 131-I for, 2184
 - from uterine cancer, 441
- primary meningiomas of, 2328
- Lung cancer
 - dyspnea in, management and significance of, 1314
 - in former smokers, 1004
 - hypercalcemia and parathyroid hormone-related protein in, 1384
 - nonsmall cell
 - adoptive immunotherapy for, 195 (editorial), 244
 - angiogenesis in, prognosis and, 409
 - blood vessel and lymphatic vessel invasion in, 2111
 - chemotherapy for, 63, 998
 - response to, glutathione S-transferase- π and, 416
 - DNA topoisomerase II α in, 729
 - immunostimulation after complete resection in, 1892
 - mitomycin C, vinblastine and carboplatin for, 1701
 - p53 mutations in, response to paclitaxel/radiation and, 1203
 - transferrin receptor in, 178 (letter)
 - weight loss in, gender and, 2119
 - small cell, DNA topoisomerase II α in, 729
- Lung transplant, lymphoproliferative disorders after, recipient origin of, 2223
- Luteinizing hormone-releasing hormone agonist, for ovarian cancer, 1452
- Luteinizing hormone-releasing hormone analogue, with bicalutamide vs. flutamide, for prostate cancer, 2164
- Lymphadenopathy, histiocytic, postarthroplasty, 834
- Lymph node metastasis
 - in colorectal cancer, sulfatides and, 43
 - in epithelial ovarian cancer, 803
 - methotrexate bound to carbon particles for, 2199
 - occult, in breast cancer, histology and, 1235
- Lymphocytes, tumor-infiltrating, for nonsmall cell lung cancer, 195 (editorial), 244
- Lymphoepithelial lesions, vs. Epstein-Barr virus-associated salivary gland cancer, 695
- Lymphoid malignancies, renal cell carcinoma and, 2421
- Lymphoid tumors, revised European-American classification of, 4
- Lymphoma. *See also* Adult T-cell leukemia/lymphoma
 - Burkitt's, revised European-American classification for, 4
 - hepatobiliary presentation of, 2011
 - HIV-related
 - centromeric instability of chromosome 1 in, 1142 (letter)
 - chemotherapy for, 517
 - Hodgkin's. *See* Hodgkin's disease
 - Ki-1 anaplastic large cell, in Asia, 1805
 - minimum residual disease in, PCR detection of, 10
 - pregnancy-associated, 304
 - renal cell carcinoma and, 2421
 - revised European-American classification for, 4
 - in Thailand, 1813
- Lymphoproliferative disorders, after pulmonary transplant, recipient origin of, 2223
- Lynch syndrome, 1149
- M**
 - Magnetic resonance imaging
 - in breast cancer, for post-chemotherapy assessment, 91
 - changes on, after stereotactic radiotherapy, for astrocytoma, 864
 - of radiation-treated cervical cancer, 2535
 - Malignant fibrous histiocytoma of lung, 2492
 - Malignant melanoma. *See* Melanoma
 - Malignant mesenchymal uterine tumors, 2543
 - Malignant pleural effusion
 - bleomycin with tetracycline for, 2498
 - tumor markers in, 736
 - Mammography
 - abnormal, follow-up timeliness after, race and, 1395
 - in elderly, 101
 - interval breast cancer and, 1220
 - knowledge and attitudes about, among low-literate, low-income women, 1912
 - in Medicare patients, influence of risk factors on, 2526
 - New Mexico Mammography Project and, 1731
 - patient and physician reminders for, 1708
 - for women 40-49 years, 572 (letter)
 - Mastectomy, for breast cancer, in elderly, 101
 - Matrix metalloproteinases-2 and 3, in urothelial cancer, recurrence and, 2379
 - Mechlorethamine, ocular toxicity of, 1359
 - Mediastinal irradiation, for seminoma, pericardial angiosarcoma after, 912
 - Medroxyprogesterone acetate, in interleukin-6 reduction, in breast cancer, 2346
 - Medullary thyroid cancer, interferon- α -2b and ocreotide for, 1114
 - Medulloblastoma, symptom duration in, stage at diagnosis and, 874
 - Melanoma
 - combined with ductal carcinoma of breast, 2515
 - computer image analysis for, 252
 - cutaneous, five-year outcome for, 427
 - cutaneous *in situ*, clinical diagnosis and therapy of, 1140 (letter)
 - desmoplastic, of oral mucosa, 383
 - HLA-DQB1*0301* in, recurrence and, 758
 - interferon for, 944
 - metastatic, complete regression of, 571 (letter)
 - metastatic uveal, 1967
 - nodular, vascular invasion in, prognosis and, 1211
 - vulvar, 2353
 - Meningioma
 - brain edema and, MIB-1 staining index for, 133
 - primary intrapulmonary, 2328
 - Metastasis
 - bone, intertrabecular patterns in, 1388

- cerebral
 from colorectal cancer, long-term survival with, 711
 histology, multiplicity, surgery and survival with, 1781
 single, surgery with radiotherapy for, 1470
 hepatic, in colorectal cancer
 focal dedifferentiation and sialyl Lewis X antigen and, 1179
 regional vs. systemic chemotherapy for, 1639
 venous invasion and, 2313
 β -human chorionic gonadotropin and, 2388
 microscopic, PCR detection of, 1 (editorial), 10
 nodal
 in colorectal cancer, sulfatides and, 43
 in epithelial ovarian cancer, 803
 methotrexate bound to carbon particles for, 2199
 occult, in breast cancer, histology and, 1235
 pulmonary
 micronodular, from papillary thyroid cancer, 131-1
 for, 2184
 from uterine cancer, 441
 single cerebral, surgery with radiotherapy for, 1470
 Methadone, for cancer pain, 852
 Methotrexate
 for AIDS-related lymphoma, 517
 bound to carbon particles, for lymph node metastases, 2199
 for gastric cancer, 1988
 ocular toxicity of, 1359
 for osteogenic osteosarcoma, 2127
 Metoclopramide, for cisplatin-associated emesis, 2193
 Metoxantrone, for breast cancer, 1906
 MIB-1 proliferation index, in transitional cell carcinoma, 827
 MIB-1 staining index, for brain edema, in meningioma, 133
 Micrometastases, PCR detection of, 1 (editorial), 10
 Mineralocorticoid deficiency, suramin and, 2411
 Minimal residual disease, PCR detection of, 1 (editorial), 10, 2445 (letter)
 Misoprostol, for prevention of chemotherapy-induced gastroduodenal mucosal injury, 1477
 Mitomycin C
 in nonsmall cell lung cancer, 1701
 ocular toxicity of, 1359
 Mitotane, for adrenocortical cancer, 1520
 Mitoxantrone
 for metastatic breast cancer, 1906
 MN-14F(ab)₂, tumor targeting with, 157
 Molecular techniques, in diagnostic pathology, 1 (editorial)
 Monitoring patient survival, 2004
 Monoclonal antibodies
¹³¹I anti-CEA, for advanced colorectal cancer, 1861
 MN-14 F(ab)₂, tumor targeting with, 157
 radiolabeled, in breast cancer detection, 2334
 Morphine, for cancer pain, dose ratios with methadone, 852
 Mott Prize lectures, 548, 553
 Multidrug resistance, CD34 expression and, in ovarian cancer cell line, 2427
 Multiple endocrine neoplasia type 2, *RET* protooncogene mutations in, 1996
 Multiple myeloma
 etoposide with autologous blood progenitor cell rescue for, 2502
 renal cell carcinoma and, 2421
 Myelodysplastic syndromes, cytarabine and etoposide for, 422
 Myocutaneous flap, gracilis, in vaginal reconstruction, sexual function after, 2229
- ## N
- Nasopharyngeal cancer
 cisplatin, 5-fluorouracil and leucovorin for, 566 (letter)
 Epstein-Barr virus-encoded RNA in, 24
 paranasopharyngeal extension of, prognosis and, 202
 perineural invasion of trigeminal nerve in, 2063
 Nasopharynx, desmoid fibromatosis of, 2572
 National Cancer Act of 1971, 2611
 25th anniversary of, 2597
 cancer research prior to, 2592
 early implementation of, 2601
 legislative process for, 2585
 personal recollections of, 2594
 preparations for, 2599
 National Cancer Advisory Board, 2603
 evaluation of National Cancer Program by, 2607
 National Cancer Data Base report
 on American Joint Committee on Cancer Staging, 1498
 on bladder cancer, 1498
 on breast cancer, for age-related characteristics and outcome, 1838
 on colon cancer, 918
 on esophageal carcinoma, 1820
 on hospital reporting, 1820
 on ovarian cancer treatment in U.S. hospitals, 2236
 on soft tissue sarcoma, 2247
 National Cancer Institute
 American Cancer Society and, 2609
 legislative history of, 2618, 2620
 National Cancer Program
 legislative history of, 2620
 National Cancer Advisory Board evaluation of, 2607
 progress in, 2043 (editorial), 2045
 National Surgical Adjuvant Breast Project Protocol B-17, pathologic findings in lobular carcinoma in situ from, 1403
 Nausea and vomiting, antiemetics for
 granisetron, dosage of, 144
 in head and neck cancer, 2450 (letter)
 placebo trials of, 2193
 Neovascularization, tumor-associated, in pancreatic cancer, 680
 Nerve block, celiac, for pancreatic cancer, 605
 Neu/ErB-2, phosphotyrosine and, in astrocytoma, 1272
 Neural network technology, in cervical screening, 112

- Neuroblastoma, with intraspinal extension, chemotherapy followed by surgery for, 311
 Neuroepithelioma, peripheral, chemotherapy, 901
 Nevi, computer image analysis for, 252
 New Mexico Mammography Project, 1731
 NK1-C3, in metastatic uveal melanoma, 1967
 nm23, in bladder cancer, 1762
 Nodal metastasis
 in colorectal cancer, sulfatides and, 43
 in epithelial ovarian cancer, 803
 methotrexate bound to carbon particles for, 2199
 occult, in breast cancer, histology and, 1235
 Non-Hodgkin's lymphoma. *See* Lymphoma
 Nonsmall cell lung cancer. *See* Lung cancer, nonsmall cell
 Nutrition, colorectal adenomatous polyps and, 723
 Nutritional supplements, in cancer treatment and prevention, 2264

O

- Occult blood testing, for colorectal cancer, haptoglobin detection in, 48
 Ocreotide, for medullary thyroid cancer, 1114
 Ocular toxicity, chemotherapeutic, 1359
 Oligodendrogliomas, Ki-67 in, prognosis and, 1107
 Omeprazole, for prevention of chemotherapy-induced gastroduodenal mucosal injury, 1477
 Oncocytomas, of submandibular gland, 2281
 Ondansetron, for cisplatin-associated emesis, 2193
 in head and neck cancer, 2450 (letter)
 Opioid rotation, for cancer pain, 852
 Oral cavity, premalignant and malignant lesions of, photodynamic therapy with 5-aminolevulinic acid for, 1374
 Oral mucosa, desmoplastic melanoma of, 383
 Oral verrucous carcinoma, p53, Rb, and cyclin D1 in, 17
 Organic mental disorders, in terminal cancer, 1131
 Osteosarcoma
 high grade, methotrexate for, 2127
 paclitaxel for, 741
 parosteal, conventional and dedifferentiated, 2136
 Ovarian cancer
 aortic and pelvic nodal metastases in, 803
 clear cell, platinum vs. nonplatinum-based chemotherapy for, 2157
 IgG in, 511
 p53 in, 179 (letter)
 circulating antibodies against, 2146
 paclitaxel for
 CA 125 as response marker in, 118
 as first-line treatment, 2366
 paraneoplastic cerebellar degeneration in, plasma-pheresis and immunoglobulin for, 2153
 secondary surgical cytoreduction for, 2049
 treatment of, National Cancer Data Base report on, 2236
 triptorelin for, 1452
 tumor markers in, transforming growth factor- α and, 1049
 Ovarian cancer cell line, CD34 expression in, multidrug resistance and, 2427
 Ovarian tumors
 borderline malignant, DNA flow cytometry in, 794
 papillary serous, of low malignant potential, 278
 specimen examination for, practice protocol for, 927
 Oxazaphosphorine cytostatics, history of, 542 (Kettering Prize lecture)

P

- p15, alterations of, in astrocytoma, 287
 p16(CDKN2), alterations of, in astrocytoma, 287
 p53
 alterations of, in astrocytoma, 287
 in bladder cancer, 1762
 cyclin D1 and, coabnormal expression of, in endometrial cancer, 1248
 in Epstein-Barr virus-associated salivary gland cancer, 695
 in gallbladder cancer, spontaneous apoptosis and, 2101
 in oral verrucous carcinoma, 17
 in ovarian cancer, circulating antibodies against, 2146
 in ovarian germ cell tumors, 179 (letter)
 in radiation-treated glottic carcinoma, prognosis and, 1693
 in T2 laryngeal cancer, radioresistance and, 991
 in testicular carcinoma in situ, 1958
 p53 mutations, in nonsmall cell lung cancer, response to paclitaxel/radiation and, 1203
 p105, in renal cell carcinoma, 819
 Paclitaxel
 for nonsmall cell lung cancer, p53 mutations and, 1203
 ocular toxicity of, 1359
 for osteosarcoma, 741
 for ovarian cancer
 CA 125 as response marker in, 118
 as first-line treatment, 2366
 as vesicant, 152
 PAI-1, in renal cell carcinoma, 487
 Pain management
 opioid rotation in, 852
 in pancreatic cancer, 605, 639
 Pancreatic cancer
 advanced
 chemotherapy for, 1300
 gemcitabine for, 633
 of body and tail, lymphatic flow and neural plexus invasion in, 2485
 chemotherapy for, 654, 688
 preclinical studies of, 674
 regional intra-arterial, 664
 clinical trials in, endpoints for, 627
 clinicopathology of, 986
 depression in, 615
 5-fluorouracil and leucovorin for, 1888
 localized, preoperative chemoradiotherapy for, 592
 management of, 579, 580
 overview of, 580
 pain management in, 605, 639

- palliative therapy for, 605, 654
 radiation therapy for, 580, 688
 intraoperative, 596
 preclinical studies of, 674
 preoperative, 592
 systemic and adjuvant therapy for, 688
 tumor-associated neovascularization and antiangiogenic strategies for, 680
 tumor markers in, 57
- Pancreatic cystic tumors, tumor markers and cyst fluid analysis in, 237
- Papillary thyroid cancer, radioactive iodine for, recurrence after, 493
- Papilloma, breast, with atypical hyperplasia, cancer risk and, 258
- Pap smear, neural network technology and, 112
- Paraneoplastic cerebellar degeneration, in ovarian cancer, plasmapheresis and immunoglobulin for, 2153
- Parathyroid hormone-related protein, hypercalcemia and, in lung cancer, 1384
- Parosteal osteosarcoma, conventional and dedifferentiated, 2136
- Patient survival monitoring, 2004
- Pediatric cancer. *See also* Children
 incidence trends in, 532
 psychosocial protocol for, 1345
 quality of life in, research in, 1333
 transitions in care of adolescent and young adult survivors of, 1340
- Pelvic autonomic nerve, preservation of, in rectal cancer, 1871
- Pelvic chondrosarcoma, prognostic factors for, 745
- Pelvic desmoplastic small cell tumor, 845
- Pelvic exenteration, gracilis myocutaneous flap in vaginal reconstruction in, sexual function after, 2229
- Pelvic nodal metastases, in epithelial ovarian cancer, 803
- Pelvic tumors, chemofiltration for, 1125
- Periampullary duodenal cancer, 568 (letter)
- Pericardial angiosarcoma, after mediastinal irradiation for seminoma, 912
- Peripheral neuroepithelioma, chemotherapy for, 901
- Peripheral primitive neuroectodermal tumor, chemotherapy for, 901
- Peritoneal carcinomatosis, in digestive endocrine tumors, 1686
- Phosphotyrosine, and Neu/ErB-2, in astrocytoma, 1272
- Photodynamic therapy, with 5-aminolevulinic acid, for oral premalignant and malignant lesions, 1374
- Pigmented skin lesions, computer image analysis for, 252
- Pineal tumors, histology of, prognosis and, 2514
- Pineoblastoma, retinoblastoma and, 858
- Pituitary tumors, WHO classification of, 502
- Plasmapheresis, for ovarian cancer with paraneoplastic cerebellar degeneration, 2153
- Plasminogen activator inhibitor, in renal cell carcinoma, 487
- Pleomorphic xanthoastrocytoma, with cortical dysplasia and neuronal tumors, 2551
- Pleural effusion
 bleomycin with tetracycline for, 2498
 tumor markers in, 736
- Polymerase chain reaction, in detection of minimal residual disease, (letter), 1 (editorial), 10
 in alveolar rhabdomyosarcoma, 1320
- Polyneuropathy, acute, cytosine and, 1899
- Polyposis, rectal, indomethacin suppositories for, 1660
- Polyps, colorectal adenomatous, calcium and vitamin supplements and, 723
- Porocarcinoma, of heel, 751
- Positron emission tomography
 applications of, 2039 (editorial)
 with F-18-fluorodeoxyglucose, for hepatic chemoembolization, 2216
- Positron emission tomography-guided stereotactic biopsy, of glioma, 1098
- Posttransplant lymphoproliferative disorders, in pulmonary transplants, recipient origin of, 2223
- Prednisone, ocular toxicity of, 1359
- Pregnancy, lymphoma in, 304
- Primitive neuroectodermal tumor, peripheral, chemotherapy, 901
- Progesterone receptors, interferon- β induction of, in endometrial adenocarcinoma, 448
- Proliferating cell nuclear antigen
 in bladder cancer, 1762
 in endometrial cancer, prognosis and, 1942
 in esophageal dysplasia, 1514 (letter)
 in in situ vs. invasive extrahepatic biliary cancer, 1881
- Proliferation-associated nuclear antigen p105, in renal cell carcinoma, 819
- Proliferation markers, in endometrial cancer, prognosis and, 1942
- Prostate cancer
 atypical adenomatous hyperplasia as precursor of, 330, 362
 bicalutamide vs. flutamide for, 2164
 CD44 in, 1461
 core needle biopsy in, 350, 366, 376
 delayed/salvage radiotherapy in, 1254
 early, biology of, 326
 free-prostate specific antigen in, 809
 hormone refractory, erythrocyte polyamine spermine levels and, 1055
 microvessel density in, prognosis and, 345
 minimum residual disease in, PCR detection of, 1 (editorial), 10, 2445 (letter)
 mRNA in, 1461
 near tetraploid, 1748
 neuroendocrine differentiation in, 357
 origins of, 330, 362
 perineural invasion of, reduced apoptotic index and, 1267

- prognostic factors for, 341, 372
 microvessel density as, 345
 prostate specific antigen as, 341
 staging and, 369
 prostate specific membrane antigen in, 809
 radiation therapy for
 delayed/salvage postoperative, 1254
 sexual function after, 1066
 screening for
 attitude survey about, 1942
 receptivity to, among urban African Americans, 471
 stage specific incidence of, 1260
 staging of, 337, 366, 369
 bone alkaline phosphatase in, 2374
 surgery for. *See* Prostatectomy
 surgical management of regional disease in, 2455
 T1-T2, percentage of carcinoma in biopsy cores in, extracapsular disease and, 1079
 Prostatectomy
 delayed/salvage radiotherapy after, 1254
 radical retropubic, survival after, 180 (letter)
 Prostate specific antigen, prognosis and, 341
 Prostatic intraepithelial neoplasia, as cancer precursor, 330, 362
 Psychiatric morbidity
 in cancer patients, 615
 in pancreatic cancer, 615
 in terminal cancer, 1131
 Psychosocial protocol, for pediatric cancer, 1345
 Pulmonary. *See also* Lung
 Pulmonary blastoma, surgery and chemotherapy for, 569
 Pulmonary malignant fibrous histiocytoma, 2492
 Pulmonary meningioma, primary, 2328
 Pulmonary metastasis
 micronodular, from papillary thyroid cancer, 131-I for, 2184
 in uterine cancer, 441
 Pulmonary transplant, lymphoproliferative disorders after, recipient origin of, 2223
- Q**
 Quality of life
 after cystectomy vs. conservative therapy, for bladder cancer, 1089
 in pediatric cancer, research in, 1333
- R**
 Race
 breast cancer prognosis and, 1241
 follow-up timeliness after abnormal mammogram and, 1395
 graft-versus-host disease and, 1492
 pediatric cancer incidence trends and, 532
 prostate cancer screening use and, 1942
 Radiation therapy
 for base of tongue cancer, 948
 for breast cancer, 1426
 in early-stage disease, 1035
 in elderly, 101
 for esophageal cancer, 1851
 chemotherapy and, 1646
 for femoral Ewing's sarcoma, 70
 for gliomatosis cerebri, 1789
 for glottic cancer, 183 (letter)
 for laryngeal cancer, resistance to, p53 status and, 991
 mediastinal, for seminoma, pericardial angiosarcoma after, 912
 for nonsmall cell lung cancer, p53 mutations and, 1203
 for pancreatic cancer, 580, 592, 596, 674, 688
 for prostate cancer
 delayed/salvage, 1254
 sexual function after, 1066
 for rectal cancer, 968
 with 5-fluorouracil, 217
 preoperative, 968
 with tumor fixation, 717
 for single cerebral metastasis, 1470
 stereotactic, for astrocytoma, magnetic resonance imaging changes after, 864
 Radical hysterectomy, with lymphadenectomy, in stage III cervical cancer, 2359
 Radical prostatectomy, survival after, 180 (letter)
 Radioactive iodine, for papillary thyroid cancer, recurrence after, 493
 Rb, in oral verrucous carcinoma, 17
 Rectal cancer. *See also* Colorectal cancer
 optimal surgery for, 1847 (editorial)
 pelvic autonomic nerve preservation in, 1871
 preoperative radiation therapy for, 968
 radiation therapy for
 with 5-fluorouracil, 217
 with tumor fixation, 717
 tumor fixation in, prognosis and, 717
 Renal cell carcinoma
 chromophobe, aggressive variants of, 1756
 5-fluorouracil and interferon- α for, 1085
 intrinsic growth deceleration of, prognosis and, 2170
 lymphoid malignancies and, 2421
 p1-5 and DNA content in, 819
 urokinase plasminogen activator in, 487
 Renal medullary carcinoma, 238
 Renal pelvic cancer, transitional cell, MIB-1 proliferation index in, 827
 Reproductive function
 in pediatric Hodgkin's disease survivors, 2020
 in Wilms' tumor survivors, 887
 Retinal pigment epithelium, congenital hypertrophy of, in familial adenomatous polyposis, 2400
 Retinoblastoma, trilateral, 858
 Retinoblastoma gene
 alterations of, in astrocytoma, 287
 in breast cancer, 1921
 13-cisRetinoic acid, for Ki-1 anaplastic large cell lymphoma, 1805
 Retinoids, ocular toxicity of, 1359

RET protooncogene mutations, in multiple endocrine neoplasia type 2, 1996
 Reverse transcriptase-PCR, for minimal disease detection, in alveolar rhabdomyosarcoma, 1320
 Revised European-American classification, of lymphoid neoplasms, 4
 Rhabdomyosarcoma, alveolar, reverse transcriptase-PCR in, minimal disease detection with, 1320
 mRNA, in prostate cancer, 1461

S

S-100, in metastatic uveal melanoma, 1967
 Salivary gland cancer
 basal cell, 2471
 Epstein-Barr virus-associated, 695
 low-grade, 958
 Sarcoma
 Ewing's
 chemotherapy, 901
 femoral, treatment of, 70
 surgical margins for, prognosis and, 892
 osteogenic
 high grade, methotrexate for, 2127
 paclitaxel for, 741
 parosteal, conventional and dedifferentiated, 2136
 soft tissue
 in children, familial cancer predisposition and, 1483
 National Cancer Data Base report on, 2247
 Screening
 for breast cancer. *See* Mammography
 in elderly, 101
 for cervical cancer, neural network technology in, 112
 for hepatocellular carcinoma, in cirrhosis, 977
 for prostate cancer
 attitude survey about, 1942
 receptivity to, among urban African Americans, 471
 Seminoma, CD44 in, 2443 (letter)
 Sex
 colon cancer and, 1666
 weight loss in nonsmall cell lung cancer and, 2119
 Sexual function
 after gracilis myocutaneous flap vaginal reconstruction, 2229
 after radiation therapy for prostate cancer, 1066
 pelvic autonomic nerve preservation for, in rectal cancer, 1871
 Sialosyl-Tn antigen, in gastric cancer, prognosis and, 171 (letter)
 Sialyl Lewis X antigen, in colorectal cancer, hepatic metastasis and, 1179
 Sickle cell disease/trait, renal medullary carcinoma and, 238
 Sinonasal tract, desmoid fibromatosis of, 2572
 Skin ulceration, paclitaxel and, 152
 Sloan Prize lecture, 558
 Small pancreatic adenocarcinoma, clinicopathology of, 986

Smokers, former, lung cancer in, 1004
 Socioeconomic factors. *See also* Race
 in mammography use, 1912
 Soft tissue sarcoma
 in children, familial cancer predisposition and, 1483
 National Cancer Data Base report on, 2247
 Sonography, for hepatocellular carcinoma screening, in cirrhosis, 977
 S-phase fraction, in endometrial cancer, prognosis and, 1942
 Squamous cell carcinoma. *See also specific sites*
 of head and neck. *See* Head and neck cancer
 vulvar, prognosis and, 273
 Staging
 American Joint Committee on Cancer Staging and, National Cancer Data Base report on, 1498
 National Cancer Data Base report on, 1498
 of prostate cancer, 337, 366, 369
 bone alkaline phosphatase in, 2374
 microvessel density in, 345
 Stereotactic biopsy, PET-guided, of glioma, 1098
 Stereotactic radiotherapy, for astrocytoma, MRI changes after, 864
 Steroids, ocular toxicity of, 1359
 Submandibular gland, oncocytomas of, 2281
 Sulfatides, in colorectal cancer, nodal metastasis and, 43
 Suramin, mineralocorticoid deficiency and, 2411
 Surgery. *See also specific procedures*
 of brain metastasis, 1781
 for breast cancer, in elderly, 101
 for Ewing's sarcoma, margins in, prognosis and, 892
 for mixed hepatocellular carcinoma and cholangiocarcinoma, 1671
 palliative, for pancreatic cancer, 605
 prophylactic, for carriers in hereditary nonpolyposis colorectal cancer, 199
 for prostate cancer. *See* Prostatectomy
 for rectal cancer, 1847 (editorial)
 Survival monitoring, 2004

T

T2 laryngeal cancer, radioresistance in, p53 status and, 991
 Tamoxifen
 for breast cancer, 1906
 ocular toxicity of, 1359
 T antigen, in gastric cancer, prognosis and, 2448 (letter)
 Tegafur, for gastric cancer, with etoposide, 211
 Telomerase, in hepatocellular carcinoma differential diagnosis, 232
 Teratoma, in testicular cancer, chemotherapy response and, 480
 Terminal cancer, psychiatric morbidity in, 1131
 Testicular cancer
 carcinoma in situ, p53 tumor suppressor gene in, 1958
 teratoma in, chemotherapy response and, 480
 Testicular dysfunction, in pediatric Hodgkin's disease survivors, 2020
 Testicular seminoma, CD44 in, 2443 (letter)

Testicular tumors, intraabdominal, torsion of, 1519 (letter)

Tetracycline, with bleomycin, for malignant pleural effusions, 2498

Thailand, non-Hodgkin's lymphoma in, 1813

Therapy. *See also specific modalities*
 of adolescent and young adult cancer survivors, 1340
 13q deletion mapping, in breast cancer, 1921

Thrombocytopenia, central line placement complications in, 2025

Thromboembolism, in clear cell ovarian carcinoma treated with platinum-based chemotherapy, 2157

Thrombosis, venous, Goshong catheter-related, 1308

Thyroid cancer
 medullary
 interferon- α -2b and ocreotide for, 1114
 prognostic factors in, 2173
 papillary
 micronodular pulmonary metastases from, 131-I for, 2184
 radioactive iodine for, recurrence after, 493

Tinnitus. *See* Ototoxicity

Tissue polypeptide antigen, in ovarian tumors, transforming growth factor- α and, 1049

Tongue base cancer, radiation therapy for, 948

Topotecan, for pediatric CNS tumors, 527

Total joint replacement, histiocytic lymphadenopathy after, 834

Transferrin receptor, in nonsmall cell lung cancer, 178 (letter)

Transforming growth factor- α
 in head and neck cancer, 1284
 tumor marker secretion from ovarian tumors and, 1049

Transforming growth factor- β , in colon cancer, 1168

Transforming growth factor- β type II receptor gene mutations, sporadic proximal colon cancer and, 2478

Transitional cell carcinoma
 of upper urinary tract, MIB-1 proliferation index in, 827
 urothelial, carboplatin for, 1775

Transplantation
 bone marrow
 graft-versus-host disease and, race and, 1492
 ocular complication in, 1359
 pulmonary, lymphoproliferative disorders after, recipient origin of, 2223

Treatment. *See also specific modalities*
 of adolescent and young adult cancer survivors, 1340

Trigeminal nerve, perineural invasion of, in nasopharyngeal cancer, 2063

Trilateral retinoblastoma, 858

Triptorelin, for ovarian cancer, 1452

Tropisetron, for cisplatin-associated emesis, in head and neck cancer, 2450 (letter)

Tumor angiogenesis. *See* Angiogenesis

Tumor-associated neovascularization, in pancreatic cancer, 680

Tumor-infiltrating lymphocytes, for nonsmall cell lung cancer, 195 (editorial), 244

Tumor markers. *See also specific markers*
 in gynecologic cancer, 511
 in ovarian tumors, transforming growth factor- α and, 1049
 in pancreatic cancer, 57
 in pancreatic cystic tumors, 237
 in pleural fluid, 736

Tumor necrosis factor- α , in colon cancer, 1168

Tumor suppressor gene, alterations of, in astrocytoma, 287

U

Ulcerative colitis, DNA hypomethylation and proliferation in rectal mucosa in, cancer risk and, 2300

Ulcers, cutaneous, paclitaxel and, 152

Ultrasonography, in hepatocellular carcinoma screening, in cirrhosis, 977

Upper urinary tract, transitional cell carcinoma of, MIB-1 proliferation index in, 827

Ureteral cancer. *See also* Urothelial cancer
 transitional cell, MIB-1 proliferation index in, 827

Urinary continence, pelvic autonomic nerve preservation for, in rectal cancer, 1871

Urokinase plasminogen activator, in renal cell carcinoma, 487

Urothelial cancer. *See also* Bladder cancer
 carboplatin for, 1775
 matrix metalloproteinases-2 and 3, recurrence and, 2379
 proliferating cell nuclear antigen, p53, nm23 and DNA content in, 1762

Uterine anomalies, in Wilms' tumor survivors, 887

Uterine cancer
 desmosomal proteins in, cellular differentiation and, 461
 IgG in, 511
 pulmonary metastases in, 441

Uterus, malignant mesenchymal tumors of, 2543

Uveal melanoma, metastatic, 1967

V

Vaginal reconstruction, gracilis myocutaneous flap in, sexual function after, 2229

Vascular permeability factor, in endometrial cancer, 458

Venous thrombosis
 in clear cell ovarian carcinoma treated with platinum-based chemotherapy, 2157
 Goshong catheter-related, 1308

Verrucous carcinoma, oral, p53, Rb, and cyclin D1 in, 17

Vesicant, paclitaxel as, 152

Vinblastine, in nonsmall cell lung cancer, 1701

Vinca alkaloids, ocular toxicity of, 1359

Vincristine

for AIDS-related lymphoma, 517

for Ewing's sarcoma, 901

Vindesine, for nonsmall cell lung cancer, 63

Vitamins

in cancer treatment and prevention, 2264

supplemental, colorectal adenomatous polyps and, 723

Vomiting, antiemetics for

granisetron, dosage of, 144

in head and neck cancer, 2450 (letter)

placebo trials of, 2193

VP-16

with autologous blood progenitor cell rescue, for myeloma, 2502

for breast cancer, 1906

for esophageal cancer, 2070

with radiotherapy, 1646

for Ewing's sarcoma, 901

for gastric cancer, with tegafur plus uracil and leucovorin modulation, 211

for myelodysplastic syndromes, 422

for nonsmall cell lung cancer, 998

Vulvar cancer, CD44 in, prognosis and, 273

Vulvar melanoma, 2353

W

Weight loss, in nonsmall cell lung cancer, gender and, 2119

Wilms' tumor, long-term survivors of, uterine anomalies in, 887

World Health Organization, classification of adenohypophyseal neoplasms, 502

X

Xanthoastrocytoma, with cortical dysplasia and neuronal tumors, 2551

Z

Zalcitabine, for AIDS-related lymphoma, 517

Authors' Index—Volume 78

A

Abati, A., 1
 Abbasciano, V., 1477
 Abbruzzese, J. L., 627
 Abe, K., 1447
 Abeler, V. M., 433, 1740
 Abraham, D. C., 91
 Abu-Abid, S., 1125
 Abu-Jawdeh, G., 454
 Acevedo, H. F., 2388
 Ackerman, D. J., 2515
 Adachi, H., 1049
 Adachi, K., 1049
 Adachi, Y., 1229
 Adamson, P. C., 527
 Adriaanse, R., 2020
 Aeppli, D. M., 1035
 Agarwal, P., 592
 Ahlgren, J. D., 654
 Ahmad, N., 592
 Ahmed, T., 1492
 Aihara, T., 1235
 Aikou, T., 226
 Aitken, J. F., 252
 Akasu, T., 1871
 Akiba, S., 226
 Akiyama, S.-I., 226
 Akiyama, Y., 2478
 Akslen, L. A., 1211
 Alberts, S. R., 764
 Albores-Saavedra, J., 958
 Aldape, H. C., 376
 Algaba, F., 376
 Allen, J. C., 527
 Allen, M. S., 2492
 AL-Tweigeri, T., 1359
 Amato, R. J., 845
 Amoaku, W. M. K., 858
 Amoroso, M., 2359
 Amos, C. I., 1004
 Anderson, N. R., 294, 300
 Angeletti, C. A., 409
 Angelopoulou, K., 2146
 Aoyagi, K., 1660
 Aquilina, R., 244
 Ariyama, J., 986
 Arlotta, F., 1114
 Arnold, C., 1912
 Arvizu, C., 1906
 Ashida, K., 232

Ashmun, R., 881
 Asoh, H., 1384
 Atkins, M. B., 195
 Atkinson, E. N., 2229
 Au, G. K. H., 202
 Averette, H. E., 1438
 Avery, R. A., 128
 Avila, N., 901
 Ayala, A. G., 745, 845, 2136
 Ayalon, D., 1452

B

Baba, S., 1671
 Babić, D., 2543
 Bacci, G., 2127
 Baer, H. U., 2318
 Bai, F., 416
 Bajetta, E., 35, 2087
 Bakardjiev, A. I., 864
 Baker, C. G., 2592
 Bakker, A., 2288
 Balis, F. M., 527, 901
 Ballo, M. S., 773
 Banner, R. O., 1582
 Bansard, J.-Y., 1055
 Baquet, C. R., 1538
 Barnes, E. L., 1284
 Barnes, L., 2471
 Barnes, P. D., 864
 Barnhill, R. L., 427
 Barón, M. G., 211
 Barr, F. G., 1320
 Barrén, R. J., 809
 Barrera, R., 2025
 Barsky, S. H., 2340
 Barth, R. J., Jr., 1168
 Bartsch, G., 809
 Bassett, L. W., 2340
 Bassukas, I. D., 2170
 Bastion, Y., 1293
 Battista, P., 2400
 Battistutta, D., 252
 Becagli, P., 2366
 Beer, M., 1492
 Behr, T. M., 157
 Behrendt, H., 2020
 Beitler, J. J., 30
 Belghiti, J., 1686
 Belldegrun, A., 2421
 Belón, J., 211

Belzile, M., 852
 Benedetti-Panici, P., 2359
 Benedict, W. F., 17
 Ben-Ezra, J. M., 2011
 Benfield, J. R., 729
 Benjamin, R., 741
 Benjamin, R. S., 2136
 Benoit, B. G., 2551
 Benson, A. B., III, 1861
 Berg, S. L., 527
 Berghout, A., 2020
 Bergström, R., 1942
 Berkel, H. (J.), 1912
 Bernades, P., 1686
 Bertino, J., 1988
 Bertram, A., 723
 Berwick, M., 427
 Beskow, C., 1798
 Bevilacqua, G., 409
 Bewsher, C., 217
 Bhoopat, L., 1813
 Bianchi, G., 977
 Biganzoli, L., 35
 Billett, A., 864
 Black, M. M., 778
 Black, P. McL., 864
 Black, R. J., 2461
 Blanco, E., 211
 Blaney, S. M., 527
 Blank, R. D., 1996
 Blankenstein, M. A., 991
 Blasius, S., 892
 Blask, A. N., 887
 Blinson, K., 1587
 Bloch, D. A., 1438
 Block, N. L., 2164
 Blume, K. G., 2502
 Blumenstein, B. A., 1085
 Blute, M., 366
 Boaziz, C., 1980
 Boccon-Gibod, L., 1079
 Bodian, C. A., 1024
 Bodo, M., 366
 Böhm, P., 1011
 Bokemeyer, C., 1958
 Bonaïti-Pellié, C., 1483
 Bonfrer, J. M. G., 118
 Bonkhoff, H., 362
 Boon, M. E., 112
 Boracchi, P., 2173

- Bordogna, G., 2087
 Borg, E., 1798
 Borgaonkar, D. S., 128
 Bornstein, B., 1426
 Bostwick, D. G., 324, 330, 362
 Boswell, W., 517
 Bouros, D., 441
 Bouzari, H., 1195
 Bowes, V. A., 809
 Bown, S. G., 1374
 Boynton, A. L., 809
 Bradlyn, A. S., 1333
 Brancaccio, L., 63
 Brasseux, C., 169
 Brawer, M. K., 345, 372
 Bréchet, J.-M., 2111
 Breitbart, W. S., 615
 Brekelmans, C. T., 1220
 Brennan, M. F., 1996
 Brenner, H., 2004
 Bressac, B., 1483
 Brice, P., 1293
 Brien, E. W., 70
 Bristow, R. E., 2049
 Brock, N., 542
 Brodovsky, H. S., 912
 Brotchi, J., 1098
 Broudy, V. C., 2223
 Brown, L. F., 454
 Browne, J. D., 383
 Brucher, J.-M., 1098
 Bruckner, H. W., 57
 Bruera, E., 852
 Brugères, L., 1483
 Bruzzi, P., 244
 Buckley, J., 517
 Buckner, J. C., 711
 Buonaccorsi, G., 1374
 Burack, R. C., 1708
 Burch, P. A., 1888
 Buresch, M., 487
 Burger, P. C., 2564
 Burgh, D. Y., 471
 Burhansstipanov, L., 1527, 1533, 1574
 Burke, T. W., 2229
 Busch, C., 369
 Busch, E., 101
 Buzzoni, R., 35
 Byers, T., 1612
 Byrd, J. C., 128
 Byrne, J., 169, 887
C
 Caan, B. J., 1666
 Cadiot, G., 1686
 Caffo, O., 1089
 Calabresi, P., 2607
 Calle-Rodrigue, R., 366
 Cama, A., 2400
 Camacho, M., 30
 Camerini, E., 35
 Camoriano, J. K., 2492
 Camp, B. J., 1168
 Cantor, S. B., 1314
 Capron, F., 2111
 Capussotti, L., 1195
 Caraceni, A., 639
 Carbone, P. P., 1633
 Carnaghi, C., 35
 Carnicelli, P., 63
 Carrasco, C. H., 2136
 Carroll, P. R., 1775
 Cascino, T. L., 711
 Cascinu, S., 1857
 Cascone, E., 1114
 CASODEX Combination Study Group, 2164
 Casper, E., 1988
 Castorina, J., 1564
 Catalano, G., 1857
 Cedermarck, B., 968
 Celentano, L., 1114
 Cha, S. S., 764
 Chaimongkol, B., 1813
 Chaitchik, S., 1125
 Chang, J.-Y., 24
 Chang, S. W., 1395
 Chang, T.-C., 794
 Chang, Y.-C., 1805
 Chao, N. J., 2502
 Chao, T.-Y., 24
 Charpentier, M.-C., 2111
 Chastagner, P., 311
 Chastang, C., 2111
 Chaves, P., 2300
 Cheek, J. H., 91
 Chella, A., 409
 Chen, S.-M., 794
 Chen, Y., 2164
 Chen, Z., 1125
 Cheng, A.-L., 1805
 Chevreton, S., 2111
 Chi, K.-H., 24
 Chlebowski, R. T., 2119
 Cho, C. C., 2070
 Cho, K. H., 1781
 Chompret, A., 1483
 Chou, H.-H., 794
 Chou, W.-C., 1805
 Chow, K.-C., 24
 Chowdhury, G. M., 827
 Choy, D. T. K., 202
 Choy, H., 1203
 Christman, K., 1988
 Chu, K.-M., 1651
 Chu, N.-M., 217
 Chua, D. T. T., 202
 Cioffi, R., 63
 Cipolla, B. G., 1055
 Clark, J. W., 688
 Clarke, D. H., 948
 Clive, R. E., 101
 Cobb, N., 1603
 Cockett, A. T. K., 357, 362
 Codegoni, A. M., 448
 Cole, B., 1203
 Cole, P., 2045
 Collet, A. M., 17
 Collette, H. J., 1220
 Colofiore, J., 1988
 Colucci, G., 1300
 Comella, G., 2087
 Comella, P., 63
 Comino, A., 1195
 Connolly, J. L., 1426, 1921
 Conti, C. J., 17
 Contos, M. J., 2011
 Conzen, S. D., 1906
 Cooksley, C. D., 1241
 Cooper, H. S., 2515
 Cooper, J., 789
 Copeland, E. M., 217
 Coppin, C. M., 480
 Corn, B. W., 2535
 Costantino, J., 1403
 Coste, M., 1980
 Cowen, M. E., 1952
 Cox, J. D., 1241
 Cozad, S. C., 1789
 Coze, C., 311
 Cravo, M., 2300
 Crawford, E. D., 1085
 Crist, W. M., 2437
 Crowley, J. J., 998
 Cubeddu, L. X., 2193
 Culligan, J. A., 2492
 Cunningham-Sabo, L. D., 1617
 Cupissol, D., 2193
 Curia, M. C., 2400
 Cusi, M. V., 2307
 Cutillo, G., 2359
D
 Dain, B. J., 1168
 Daling, J. R., 1417
 Dalmau, J. O., 2153
 Dalton, R. J., 1888
 Daly, J. M., 1820
 D'Amato, M. S., 751
 Damhaut, P., 1098
 Darling, R. R., 1731
 DaSilva, V. F., 2551
 Davelaar, E. M., 118
 David, Y. B., 2153
 Davis, A. C., 2585

Davis, C. J., Jr., 128
 Davis, S., 532
 Davis, S. M., 1617, 1629
 Davis, T. C., 1912
 De Bellis, R., 2510
 DeCambra, H., 1582
 Decapeptyl Ovarian Cancer Study Group, 1452
 De Cataldis, G., 63
 de Jong, P. T. V. M., 1967
 DeLaney, T. F., 901
 Delbeke, D., 2216
 Del Bo, R., 2173
 Delepine, G., 2127
 Delepine, N., 2127
 Del Ferro, E., 1857
 Delgado, R., 958
 Demers, L., 267
 DePoli, F., 1701
 Desbois, J.-C., 2127
 de Sousa, L. S., 2300
 de Vecchi, C. A., 2111
 Dews, P., 1708
 Diamandis, E. P., 2146
 Di Bartolomeo, M., 2087
 Dignan, M., 1587
 Di Leo, A., 35
 Dimich, A. B., 1996
 D'Incalci, M., 448
 Di Rocco, M., 2334
 di Sant'Agnese, P. A., 357, 372
 DiTucci, J. A., 1617
 Divine, M., 1293
 Djalilian, H. R., 1781
 Dmuchowski, C. F., 948
 Doh, K., 1447
 Dorr, R. T., 152
 Douglas, T., 809
 Driscoll, D. L., 2157
 Duggal, N., 2551
 Duncan, G., 1470
 Dunn, R., 157
 Dunst, J., 892
 Dupont, W. D., 258
 Dutcher, J. P., 2510
 Dutta, S., 1861
 Dvorak, H. F., 454

E

Easaw, S. J., 1492
 Eberle, V., 2170
 Eberlein, T., 1921
 Echave-Sustaeta, J., 736
 Edwards, S., 1666
 Ehya, H., 2515
 Eisenberg, P. D., 144
 Elashoff, R., 2421
 Elias, L., 1085
 Ellerhorst, J. A., 845

Ellis, G. L., 2281
 El-Mofty, S. K., 1693
 Elting, L. S., 1314
 Emad, A., 2498
 Emami, B., 1693
 Emi, M., 1929
 Emons, G., 1452
 Encabo, G., 2374
 Enker, W. E., 1847
 Enos, R., 1582
 Epstein, J. I., 350, 376
 Erickson, S. J., 809
 Ernest, M. L., 1775
 Escalante, C. P., 1314
 Espina, B., 517
 Espinosa, E., 211
 Estelberger, W., 511
 Estenoz-Alfaro, J., 736
 Ettinger, D. S., 144
 Ewing, C. A., 1722
 Eyre, H. J., 2609

F

Fan, K. F. M., 1374
 Fang, J.-Y., 532
 Fantino, G., 244
 Farnell, G. F., 711
 Farr, G. H., Jr., 764
 Farrow, G. M., 376
 Fassl, H., 1452
 Favaretto, A., 1701
 Feldman, E. J., 1492
 Feliu, J., 211
 Fell, S., 30
 Fellin, G., 1089
 Fenoglio-Preiser, C. M., 704, 2307
 Fermé, C., 1293
 Ferrant, A., 1293
 Ferrari, L., 35
 Festi, G., 1701
 Fetsch, J. F., 79
 Feuer, E. J., 778
 Feunteun, J., 1483
 Ficari, F., 2400
 Figge, H., 1461
 Figge, J., 1461
 Figlin, R., 2421
 Figlin, R. A., 998
 Fine, J. A., 427
 Finkelstein, S. D., 2288
 Fiorentino, M. V., 1701
 Fippin, L. J., 1775
 Fishback, N. F., 729
 Fisher, B., 1403, 1470
 Fisher, E. R., 1403
 Fisher, H. A. G., 1461
 Fitts, D., 144
 Flanigan, R. C., 1085
 Fléjou, J.-F., 1686

Fleming, I. D., 1498
 Fleshner, N. E., 1505
 Foley, G. V., 1340
 Fontanini, G., 409
 Forde, K. A., 723
 Forman, S. J., 1899
 Forsslund, G., 1748
 Fortunato, S., 1300
 Foster, G., 1470
 Fox, S. A., 2526
 Frankendal, B., 1798
 Fransson, P., 1066
 Frappaz, D., 311
 Fraumeni, J. F., Jr., 548
 Frazier, A. J., 948
 Fredericks, L., 1592, 1623
 Fremgen, A., 101
 Friedman, C., 144
 Friedman, G. D., 1666
 Friedman, H. S., 874
 Fruttero, A., 1195
 Fueger, J. J., 1004
 Fugate, M. L., 1617
 Fujii, A., 2379
 Fujii, K., 2078
 Fujii, S., 1248
 Fujimoto, K., 396
 Fujimoto, N., 2379
 Fujisawa, T., 1892
 Fujishima, M., 1660
 Fujita, A., 2210
 Fujita, S., 1871
 Fujiwara, Y., 2094
 Fujiya, T., 2313
 Fukuyama, Y., 1384
 Fuller, A. F., Jr., 441
 Furman, W. L., 2437
 Furukawa, H., 986
 Futagami, F., 2485

G

Gabarre, J., 1293
 Gage, I., 1426, 1432, 1921
 Gajjar, A., 881, 2437
 Gales, T., 2515
 Gallagher, J. G., 1888
 Gama-Rodrigues, J. J., 2288
 Garancini, P., 2334
 Garbowski, G. C., 723
 García-Alfonso, P., 211
 García-Girón, C., 211
 Garrido, P., 211
 Gaspar, L., 1470
 Gattani, A. M., 57
 Gebbia, N., 1300
 Gebbia, V., 1300, 2087
 Gefeller, O., 2004
 Gelb, A. B., 304
 Gelman, R., 1426, 1921

George, J., 1708
 George, W. J., 664
 Gershenson, D. M., 2229
 Ghandehari, S., 2340
 Ghossein, R. A., 10
 Gibbons, R. P., 2455
 Gigaud, M., 311
 Gill, P. S., 517
 Gilliland, F. D., 1731
 Gimenez-Conti, I. B., 17
 Gimotty, P. A., 1708
 Gion, T., 2094
 Giordano, T. J., 2184
 Giotta, F., 1300
 Gitsch, G., 273
 Giuliano, A., 1629
 Giuseppe, S., 1300
 Glass, J., 1912
 Glaubitz, M., 2353
 Gleave, M. E., 480
 Glicksman, A. S., 688
 Glória, L., 2300
 Gnepp, D. R., 2572
 Godschalk, J. J. C. J., 1107
 Gohji, K., 2379
 Goldenberg, D. M., 157
 Goldman, H., 2261
 Goldman, S., 1098
 Gollerkeri, A., 1203
 Gómez-Navarro, J., 211
 Goodwin, J. W., 998, 1085
 Gotay, C. C., 1582
 Goto, T., 1119
 Gould, J. R., 1308
 Goumnerova, L. C., 864
 Graffer, U., 1089
 Gralla, R. J., 2193
 Grandis, J. R., 1284
 Grant, M. D., 91
 Gray, D. J., 2070
 Green, A. C., 252
 Gregg, S., 2359
 Greschniok, A., 1011
 Grianti, C., 1857
 Grignon, D. J., 337, 369
 Groch, M. W., 1861
 Groeger, J. S., 2025
 Gross, M. D., 2184
 Grossberg, H., 267
 Guccion, J. G., 751
 Gueli, C., 977
 Guidi, A. J., 454
 Guillé, F., 1055
 Guinee, D. G., Jr., 729
 Gullo, M., 2173
 Guolo, P., 237
 Gurney, J. G., 532, 1260

Gustafson, G. S., 948
 Gutman, M., 1125

H

Haase, G. M., 1330
 Haddock, M. G., 2564
 Haeusler, G., 273
 Hagiwara, A., 2199
 Hagiwara, S., 133
 Hall, W. A., 1781
 Halperin, E. C., 874
 Halpern, H. J., 1722
 Halyard, M. Y., 2492
 Hamanaka, Y., 43
 Hamano, K., 403
 Hammond, O. W., 1582
 Hampe, D. W., 91
 Hampton, J. W., 1545
 Hankey, B. F., 778
 Hansen, H. J., 157
 Hanson, J., 852
 Haon, C., 1980
 Hara, N., 416
 Harle, T. S., 1314
 Harlow, E., 558
 Harmantas, A., 1639
 Harms, S. E., 91
 Harn, H.-J., 24
 Harris, A. C., 2011
 Harris, C. V., 1333
 Harris, J. E., 128
 Harris, J. R., 1426, 1921
 Hart, W. R., 278
 Hartmann, O., 311
 Hartsock, R. J., 2388
 Hartung, R., 487
 Hauck, W., 2535
 Haughey, B. H., 1693
 Haynes, H., 30
 Haynie, T. P., 493
 Healey, J. H., 70
 Hedlund, N., 1582
 Heffner, D., 2572
 Heideman, R. L., 527, 881
 Heikens, J., 2020
 Heil, E., 948
 Heimann, R., 1722
 Heinecke, A., 2353
 Hejna, M., 1646
 Helpap, B., 362
 Hempling, R. E., 2157
 Henderson, I. C., 789
 Henley, J., 2572
 Henske, E. P., 1756
 Henson, D. E., 366, 927, 2582
 Herr, H. W., 1505
 Herskovic, A., 1851
 Hetelekidis, S., 1426
 Hiasa, Y., 287

Hideshima, T., 2346
 Higashi, T., 232
 Hijazi, Y. M., 901
 Hildebrand, J., 1098
 Hillmann, A., 892
 Hino, N., 232
 Hino, T., 695
 Hinton, D. R., 1899
 Hirakawa, N., 390
 Hirohashi, S., 1179
 Hirota, C., 1660
 Ho, D., 48
 Hochholzer, L., 2328
 Hockenberry-Eaton, M., 1345
 Hodge, F. S., 1592, 1623
 Hoffman, J. P., 592
 Hoffmann, C., 892
 Hofmann, R., 487
 Hofmockel, G., 2170
 Hoj, P. B., 48
 Holden, J. A., 729
 Holleb, A. I., 2590
 Holliday, M., 1564
 Holm, R., 433
 Holm, T., 968
 Holmes, E. H., 809
 Homer, M. J., 1432
 Homesley, H. D., 2193
 Homma, H., 1049
 Honma, K., 1388
 Hop, W. C. J., 1107
 Hopper, C., 1374
 Hordijk, G. J., 991
 Hori, Y., 1229
 Horowitz, M. E., 527, 901
 Horvath, E., 502
 Horvath, K., 723
 Horwitz, E. M., 948
 Hoshiai, H., 1447
 Hoshima, M., 2199
 Houn, F., 2526
 Hsueh, S., 794
 Hu, S.-X., 17
 Hu, W. W., 2502
 Hu, X., 30, 2078
 Huang, K.-G., 794
 Huang, Y., 2025
 Hugenholtz, H., 1470
 Hughes, C. K., 1558
 Hui, Y., 1564
 Hui, Y. Z., 704
 Humphrey, P. A., 372
 Hundahl, S. A., 1829
 Hundeiker, M., 2353
 Hunt, W. C., 1731
 Hutchins, L. F., 1851
 Hutter, R. V. P., 369, 2581

I

Ianniello, G. P., 63
 Ichinose, Y., 1384
 Ide, M., 133
 Igawa, M., 1762
 Iguchi, H., 1384
 Iida, M., 1660
 Ilaban, E. K., 1582
 Ilić, J., 2543
 Imanishi, T., 2199
 Imaoka, S., 1235
 Imayama, S., 1229
 Inaji, H., 1235
 Inbar, M., 1125
 Ingle, J. N., 764
 Ino, Y., 1179
 Inoue, E., 396
 Inoue, Y., 1447
 Intragumtornchai, T., 1813
 Ioachim, H. L., 4
 Iriya, K., 2288
 Ishibe, T., 1762
 Ishida, Y., 422, 695
 Ishiguro, S., 1187
 Ishikawa, T., 2478
 Ishitani, K., 1131
 Ishizuka, I., 43
 Isozaki, H., 2078
 Issell, B. F., 1582
 Ito, N., 1929
 Ito, T., 422
 Itoh, E., 461
 Itoiz, M. E., 17
 Iwakiri, R., 396
 Iwama, T., 2478
 Iwamoto, A., 1935
 Iwanaga, R., 2478
 Iwase, T., 1929

J

Jackisch, C., 2353
 Jackson, R. H., 1912
 Jacobs, E. L., 998
 Jacobson, J., 901, 1851
 Jaffe, N., 2136
 Jakacki, R. I., 527
 Jamadar, D. A., 2184
 Janisch, L., 2411
 Jarosinski, P., 901
 Jenny, A. B., 1789
 Jensen, O. A., 1967
 Jensen, R. A., 258, 1607
 Jessup, J. M., 918, 1829
 Jimbo, M., 133
 Joe, J., 1629
 Johnson, M. E., 745
 Jonas, U., 1958
 Jonassen, J., 1958

Jones, J. J., 2070
 Jones, R. C., 91
 Jones, S. E., 91
 Jukić, S., 2543
 Jürgens, H., 892
 Juweid, M., 157

K

Kagawa, S., 827
 Kainz, C., 273
 Kaiserling, E., 1011
 Kajiyama, K., 2094
 Kakizoe, T., 986
 Kakugawa, Y., 2313
 Kallakury, B. V. S., 1461
 Kamel, O. W., 304
 Kamidono, S., 2379
 Kamiyama, Y., 2313
 Kanayama, H.-O., 827
 Karasawa, E., 986
 Karlan, B. Y., 2049
 Karnell, L. H., 1820, 2247
 Karp, D. D., 195
 Kasumi, F., 1929
 Kato, T., 403
 Kattan, M. W., 1267, 1952
 Kaufman, P. A., 1906
 Kaufman, R., 1461
 Kauppila, A., 1452
 Kaur, J. S., 1578
 Kausik, S. J., 1461
 Kawana, T., 1935
 Kawanishi, M., 1762
 Kawasaki, M., 416
 Kayahara, M., 2485
 Kazerooni, E. A., 2184
 Keala, J., 1545
 Keidan, R. D., 948
 Kelly, K. M., 1320
 Kelsen, D., 1988
 Kemeny, M., 101
 Kenemans, P., 118
 Kennedy, A. W., 278
 Kenney, L. B., 169
 Kenny, G. M., 809
 Kepes, J. J., 1789
 Kerlikowske, K., 1395
 Kestle, J., 1470
 Key, C. R., 1731
 Kido, Y., 1794
 Killion, M. J., 912
 Kilpatrick, S. E., 383
 Kim, A., 2340
 Kim, R., 2288
 Kimura, T., 1794
 Kimura, W., 1677
 Kindblom, L.-G., 79
 King, S., 2535
 King, T., 1203

Kinsella, T. J., 598
 Kinugasa, N., 232
 Kipnis, P., 1623
 Kish, J., 1085
 Kish, S. K., 1314
 Kitagawa, H., 2485
 Kitayama, J., 1677
 Kjørstad, K. E., 1740
 Klausner, J. M., 1125
 Klein, M. J., 1043
 Klimstra, D., 958
 Klocker, H., 809
 Knipmeyer, M. C., 2618
 Knox, S. M., 91
 Kobayashi, K., 2411
 Kodaira, S., 403
 Koehli, O. R., 1438
 Koehler, K. M., 1617
 Koelbl, H., 273
 Kojima, K., 827
 Kok, M. R., 112
 Kokoska, M. S., 1693
 Kolvenbag, J. C. M., 2164
 Komiyama, S., 390
 Komiyama, T., 2379
 Kondo, Y., 695
 Konishi, N., 287
 Konno, A., 695
 Konno, H., 1671
 Kornek, G. V., 1646
 Kornstein, M. J., 2011
 Koss, M. N., 729, 2328
 Kovač, D., 2543
 Kovacs, K., 502
 Koyama, H., 1235
 Koyama, T., 396
 Koyama, Y., 403
 Kozuru, M., 1119
 Krähenbühl, L., 2318
 Krasnow, S. H., 751
 Kris, M. G., 2193
 Krishnadath, K. K., 1107
 Kristensen, G. B., 433
 Kristt, D. A., 1272
 Krüber, S., 1011
 Krook, J. E., 764
 Kropveld, A., 991
 Kros, J. M., 1107
 Krosnick, S. H., 1432
 Kubo, O., 133
 Kuczyk, M. A., 1958
 Kudo, R., 461
 Kuehn, N., 852
 Kugler, J. W., 1888
 Kullander, S., 1452
 Kun, L., 881
 Kunkel, L. A., 2421
 Kurachi, H., 1049

Kuratomi, Y., 390
 Kuriya, S.-I., 422
 Kurokawa, Y., 827
 Kürzl, R., 2353
 Kwakwa, H., 1203
 Kwong, D. L. W., 202

L

Lacerna, M. D., 948
 Lach, B., 2551
 Lagasse, L. D., 2049
 Lahousen, M., 511
 Lai, C.-H., 794
 Lai, G.-M., 1972
 Lake, D. E., 1492
 Lam, K.-Y., 1651
 LaMarca, K., 1633
 Lamki, L. M., 2039
 Lando, J. F., 1731
 Landoni, F., 448
 Lane, J. M., 70
 Lanfranchi, H., 17
 Lange, B. J., 527
 Langer, B., 1639
 Laniado, M., 1011
 LaQuaglia, M. P., 1996
 Lara, J. F., 2515
 Laskin, W. B., 79
 Lattes, R., 1024
 Läufer, J. M., 2318
 Laufman, L. R., 2070
 Laurell, G., 1798
 Lauria, M. M., 1345
 Lauro, S., 1701
 Lauwers, G. Y., 217
 Law, S. Y.-K., 1651
 Lawrence, T. S., 674
 Lawrence, W., Jr., 2603
 Leake, B., 2526
 Le Bihan, C., 1483
 Lee, C. S., 1881
 Lee, J. E., 758
 Lefkowitz, M., 79
 Lehmer, A., 487
 Leitão, C. N., 2300
 Leitzel, K., 267
 Lekhakula, A., 1813
 LeMarbre, P., 1906
 Lemerle, J., 1483
 Leone, B. E., 2334
 Lepage, E., 1293
 Letton, A. H., 2597
 Lev, D., 1125
 Levenback, C., 2229
 Levine, A. M., 517
 Levine, B., 30
 Levine, M., 1470
 Levitan, M., 2153
 Levitt, S. H., 1035, 1254

Levivier, M., 1098
 Li, F. P., 553
 Li, S.-F., 1248
 Liang, D.-C., 1805
 Liaw, C.-C., 1972
 Liddil, J. D., 152
 Lieber, M., 369
 Liessi, G., 237
 Ligi, M., 1857
 Lillemoe, K. D., 605
 Lillington, L. M., 2119
 Linke, K. A., 741
 Linver, M. N., 1731
 Liotta, L. A., 1
 Lipton, A., 267, 789
 Liu, Q., 2437
 Livingston, R. B., 998
 Lloyd, R. V., 502
 Lobel, B., 1055
 Loeffler, J. S., 864
 Logothetis, C., 369
 Löhrs, U., 1452
 Lokich, J. J., 294, 300
 Lombardi, A., 63
 Lombardi, G., 1114
 Lomonico, S., 448
 Long, G. D., 2502
 Look, T., 881
 Lopez, F., 1203
 Lopez-Beltran, A., 376
 López-Encuentra, A., 736
 Lorente, J. A., 2374
 Losa, G., 448
 Loughlin, K. R., 1756
 Love, S., 2340
 Love, S. M., 1921
 Lowe, B. A., 1085
 Lu, M., 758
 Lu, Y., 1438
 Lucchi, M., 409
 Lucchini, V., 448
 Luce, P., 1545
 Luce-Aoelua, P. H., 1533
 Luciani, L., 1089
 Lui, C.-C., 2063
 Luider, T. M., 1967
 Luna, M., 17
 Luo, X., 881
 Lupoli, G., 1114
 Lupulescu, A. P., 2264
 Luyten, G. P. M., 1967
 Lynch, H. T., 1149
 Lyons, M. K., 2564

M

Ma, L. T., 1651
 Macdonald, J. S., 1851
 Machtens, S., 1958
 Mackey, J. R., 1359

MacLean, W. E., Jr., 1340
 MacRobert, A. J., 1374
 Maeda, T., 2094
 Magalotti, D., 977
 Mahmoud, H. H., 2437
 Mahoney, M. C., 1533, 1574
 Mahran, H., 372
 Mailliard, J. A., 1888
 Maiorino, A., 63
 Majello, E., 1300
 Maksem, J., 376
 Malkin, M. G., 2153
 Malone, K. E., 1417
 Mancuso, S., 2359
 Mandeli, J., 57
 Maneschi, F., 2359
 Mangili, F., 2334
 Mangioni, C., 448
 Mann, J. R., 858
 Mansfield, P. F., 758
 Manzullo, E. F., 1314
 Marchesini, G., 977
 Marcove, R. C., 70
 Mariani, L., 35
 Mariani-Costantini, R., 2400
 Markle, B. M., 887
 Marks, G., 717
 Marks, L. B., 2564
 Marmuse, J.-P., 1686
 Marsh, R. de W., 217
 Martin, C. G., 1314
 Martin, D. S., 1988
 Martin, N. G., 252
 Martinez, A. A., 948
 Martuscello, T. A., 1168
 Martín-Escribano, P., 736
 Marušić, M., 2543
 Masuda, M., 390
 Mathew, P., 881
 Matsumoto, T., 1660
 Matsunaga, D. S., 1582
 Matsuzaki, O., 695
 Mauer, A. M., 1345
 Maurer, L. H., 1906
 Maurer-Schultze, B., 2170
 Mazer, M. J., 2216
 McCombs, M. M., 2340
 McGinnis, L. S., 918
 McGrory, G., 471
 McKee, L., 471
 McKenzie, I. F. C., 48
 McKnight, B., 1417
 McLeod, D. G., 809
 Meadows, A. T., 169
 Mechinaud, F., 311
 Medini, E., 1254
 Medini, I., 1254
 Meekungwal, P., 1813

Meis-Kindblom, J. M., 79
 Melhem, M. F., 1284
 Melioli, G., 244
 Memoli, V. A., 1168
 Mempel, V., 2353
 Menck, H. R., 918, 1498, 1505, 1820,
 1829, 1838, 2236, 2247
 Mencucci, R., 2400
 Mendenhall, W. M., 217
 Meranze, S. G., 2216
 Messori, A., 2366
 Mettler, J. M., 1861
 Mettlin, C., 1505
 Mettlin, C. J., 2043
 Meyers, P. A., 70
 Michalek, A. M., 1533, 1574
 Michel, A. G., 1722
 Michielutte, R., 1587
 Michon, J., 311
 Mignon, M., 1686
 Mikuni, J., 2313
 Miles, B. J., 1952
 Milestone, B., 2535
 Miller, A. A., 789
 Miller, M. A., 2307
 Mills, J. L., 169
 Mills, L. E., 1906
 Mimori, K., 1229
 Mina, B., 2025
 Minagawa, H., 1131
 Minderman, H., 2427
 Minderman, M. D., 2427
 Mintz, A. H., 1470
 Minuti, P., 244
 Mira, F. C., 2300
 Mirabelli, S., 244
 Mishra, S. I., 1533
 Mitchell, M. F., 2229
 Mittal, B. B., 1861
 Mittal, R. R., 1861
 Miyairi, Y., 422
 Miyake, A., 1049
 Miyazaki, I., 2485
 Miyazaki, K., 2101
 Mizuguchi, M., 396
 Mohiuddin, M., 717
 Mokuau, N. K., 1558
 Moncrease, A., 1708
 Montie, J. E., 341, 369, 1260
 Montironi, R., 362
 Moore, C. L., 294, 300
 Moore, I. M. (Ki), 1333
 Moore, M., 627, 633
 Mooy, C. M., 1967
 Morabito, A., 1701
 Moran, C. A., 2328
 Morantz, R. A., 1789
 Moreschi, M., 2087

Morgan, T., 809
 Mori, M., 461, 1229
 Morichika, H., 43
 Morishige, K.-I., 1049
 Moriya, Y., 1179, 1871
 Morote, J., 2374
 Morris, M., 2229
 Morton, R. F., 1888
 Moseley, S. H., 741
 Mostofi, F. K., 366
 Motokura, T., 2210
 Motomura, K., 1235
 Mott, L. A., 1906
 Moulinoux, J.-P., 1055
 Moutou, C., 1483
 Muchmore, J. H., 664, 941
 Muirhead, M., 998
 Mulagha, M. T., 789
 Muller, S., 2471
 Munakata, A., 1187
 Murai, K., 422
 Murakami, K., 986
 Muranishi, S., 2199
 Muro, H., 1671
 Murphy, G. P., 324, 372, 809, 1505,
 1829, 2599, 2601
 Murray, J. A., 745, 2136
 Murray, N., 480
 Mussi, A., 409
 Muta, K., 1119
 Muto, T., 1179, 1677
 Muxi, P., 2510
 Myers, J., 1203
 Myers, R. E., 471

N

Nabholtz, J.-M., 1359
 Nadj, M., 1438
 Nagakawa, T., 2485
 Nagami, H., 1762
 Nagano, M., 1119
 Nagao, K., 695
 Nagao, T., 695
 Nakagawa, S., 1935
 Nakaizumi, A., 986
 Nakaji, S., 1187
 Nakajima, M., 2379
 Nakamura, M., 287
 Nakamura, S., 1671
 Nakamura, Y., 1929, 2210
 Nakanishi, Y., 416
 Nakashima, T., 390
 Nakatsukasa, H., 232
 Nakazawa, S., 986
 Nanbara, S., 1229
 Nandy, I., 1912
 Nápoles-Springer, A., 1395
 Narigasawa, Y., 422
 Nash, M., 881

Nathanson, L., 944
 Nathwani, B., 517
 National Cancer Institute Breast
 Cancer Screening Consortium,
 2526
 Navari, R., 789
 Nedellec, G., 1293
 Negrin, R. S., 2502
 Nei, H., 461
 Nelson, G., 471
 Nelson, G. A., 471
 Neugut, A. I., 723
 Ng, S.-H., 1972
 Nguyen, M., 2340
 Nicholson, H. S., 169, 887
 Nielsen, I., 1477
 Nielsen, M. L., 927
 Nierengarten, M. E., 1035
 Nihei, Z., 2478
 Nikaido, T., 1248
 Nilsson, B., 1748
 Nilsson, S., 1942
 Nishi, N., 2478
 Nishikubo, C. Y., 2421
 Nixon, A. J., 1426, 1921
 Noda, K., 1447
 Noffsinger, A. E., 704, 2307
 Noguchi, S., 1235
 Nola, M., 2543
 Nordström, B., 1942
 Norman, M. G., 2564
 Nouse, K., 232
 Nussbaum, E. S., 1781

O

Obata, K., 1447
 Oberheuser, F., 1452
 O'Brien, R. T., 1333
 O'Connell, M. J., 711
 O'Dwyer, P., 592
 Ogata, E., 2210
 Ogawa, M., 2346
 Ogawa, N., 403
 Ohgaki, M., 2199
 Ohkawa, J., 2379
 Ohmura, G., 1447
 Ohta, T., 2485
 Ohyama, T., 2199
 Okada, S., 986
 Okada, Y., 1794
 Okajima, K., 2078
 Okamura, T., 1794
 Onda, T., 803, 1935
 Oniga, F., 1701
 Ono, H., 2313
 Ono, M., 1179
 Openshaw, H., 1899
 Ordóñez, A., 211
 Oron, D., 1125

O'Rourke, P. K., 252
 Orozco, R. E., 376
 Ortmann, O., 1452
 Ortuño-de-Solo, B., 736
 Osborn, K. L., 1629
 Ossana, L., 1701
 Osteen, R. T., 101, 1838
 Ouchi, K., 2313
 Ozaki, T., 892

P

Paccagnella, A., 1701
 Pacelli, A., 376
 Packer, R. J., 527
 Padmore, R. F., 2515
 Page, D. L., 258
 Paik, S. M., 1403
 Pairojkul, C., 1813
 Pairolero, P. C., 2492
 Palekar, A. S., 1403
 Palmirotta, R., 2400
 Palomares, M. R., 2119
 Panella, T. J., 1851
 Papadakis, K., 441
 Papadopoulos, N. E., 741
 Parker, J., 517
 Parkes, S. E., 858
 Parkinson, D. R., 680
 Parsons, S. K., 1333
 Partridge, E. E., 2236
 Pasquali, C., 237
 Passagia, J. G., 311
 Passik, S. D., 615
 Patchefsky, A. S., 2515
 Patel, S. R., 741
 Patterson, A. L., 2164
 Patterson, K., 1333
 Patterson, R. H., 751
 Pawletko, T. M., 1345
 Pedrazzoli, S., 237
 Peeters, P. H., 1220
 Pei, X. H., 416
 Pereira, J., 852
 Pérez-Stable, E. J., 1395
 Perkins, P., 1241
 Perzin, K. H., 1024
 Pete, J. E., 1633
 Peters, G. N., 91
 Petrovečki, M., 2543
 Pezzella, G., 1300
 Pfitzner, J., 252
 Phillips, J. L., 1498, 2236
 Phillips, P. C., 527
 Piccirillo, J. F., 1693
 Pilotti, S., 2173
 Pinotti, H. W., 2288
 Pinson, C. W., 2216
 Pinto, A., 2300
 Pirotte, B., 1098

Pisansky, T. M., 376
 Pisi, E., 977
 Pitt, H. A., 605
 Piver, M. S., 2157
 Placucci, M., 2173
 Plager, C., 741
 Plantaz, D., 311
 Platsoucas, C. D., 758
 Plomer, K., 1527
 Pluda, J. M., 680
 Pluth, J. R., 2492
 Pointner, J., 809
 Poisson, N., 1483
 Pollock, B. H., 1333
 Pollock, R. E., 2247
 Polverosi, R., 237
 Pomeroy, S. L., 864
 Ponte, M., 244
 Poplack, D. G., 527
 Poplin, E. A., 1851
 Portenoy, R. K., 627, 639
 Posner, S. F., 1395
 Post, J., 1967
 Potter, J. D., 1666
 Powell, C. B., 834
 Powers, C., 1722
 Prayoonwiwat, W., 1813
 Preslan, J. E., 664
 Price, K. J., 1314
 Provost, E. M., 1598
 Prudent, J., 2111
 Przygodzki, R. M., 729
 Pui, C.-H., 2437

Q

Quan, V., 1988
 Quemener, V., 1055
 Quina, M., 2300

R

Rabbani, F., 480
 Räber, G., 2353
 Raderer, M., 1646
 Ragde, H., 369, 809
 Raghu, G., 2223
 Rasheed, S., 517
 Ratain, M. J., 2411
 Rathbone, M. P., 1470
 Ratliff, C. R., 2229
 Ratto, G. B., 244
 Ravery, V., 1079
 Raymond, A. K., 2136
 Raymond, E., 1980
 Reaman, G. H., 169, 527, 887, 1330
 Recant, W., 1722
 Recht, A., 1426, 1921
 Recio, F. O., 2157
 Reddy, P. K., 1254

Regine, W. F., 717
 Reinthaller, A., 273
 Reissigl, A., 809
 Reman, O., 1293
 Renshaw, A. A., 1756
 Reuter, V. E., 369
 Reveille, J. D., 758
 Reynolds, J. C., 2288
 Rezaian, G. R., 2498
 Rhoads, J. E., 2594
 Ribechini, A., 409
 Ribeiro, R. C., 2437
 Ribeiro, U., Jr., 2288
 Riccardi, F., 1300
 Rinehart, J. J., 998
 Ritchey, A. K., 1333
 Ritenbaugh, C., 1629
 Rivera, G. K., 2437
 Robertson, J. M., 627, 674
 Robison, L. L., 169, 532
 Roche, P. R., 764
 Rochemaure, J., 2111
 Rodriguez, B., 1592
 Rodríguez-Bigas, M. A., 199
 Rodu, B., 2045
 Roetzheim, R., 2526
 Rompel, R., 2353
 Romsdahl, M. M., 745
 Rosai, J., 10
 Rosen, B., 2146
 Rosen, G., 2127
 Rosen, H., 1646
 Rosen, P., 2421
 Rosen, S. T., 1861
 Rosenberg, R. D., 1731
 Rosmarin, A., 1203
 Ross, A., 1564
 Ross, J. A., 532
 Ross, J. S., 1461
 Ross, M. I., 758
 Rothenberg, M. L., 627
 Rotstein, L. E., 1639
 Roush, G. C., 427
 Ruà, S., 1195
 Rübe, C., 892
 Rubenstein, E. B., 1314
 Rubie, H., 311
 Rubin, J., 1888
 Ruby, S. G., 927
 Ruccione, K., 1340
 Ruiz, J. M., 35
 Rush, W., 2328
 Russell, S., 1527
 Rustum, Y. M., 2427
 Ruszniewski, P., 1686
 Rutqvist, L.-E., 968

S

- Sabath, D., 2223
 Sabioncello, A., 2543
 Safatle-Ribeiro, A. V., 2288
 Safran, H., 1203
 Saisho, H., 986
 Saito, T., 461
 Saitoh, K., 2478
 Sakabe, T., 403
 Sakaguchi, T., 1671
 Sakai, T., 396
 Sakaki, T., 287
 Sakakura, C., 2199
 Sakamoto, K., 2478
 Sakamoto, M., 1179
 Sakata, H., 396
 Sako, S., 2078
 Sakr, W. A., 337, 366
 Salazar, H., 592
 Salerno, M. G., 2359
 Salhany, K. E., 258
 Sallan, S. E., 527
 Saltz, L., 1988
 Salvatore, M., 1114
 Samowitz, W., 1666
 Sampietro, G., 2173
 Sandlund, J. T., 2437
 Sankaranarayanan, R., 2461
 Santambrogio, G., 2334
 Santana, V. M., 2437
 Saotome, K., 1388
 Sarosdy, M. F., 2164
 Sartore, F., 1701
 Sartori, S., 1477
 Sasatomi, E., 2101
 Sassi, I., 2334
 Sathiseelan, V., 1861
 Savino, D. A., 91
 Sawai, K., 2199
 Sayre, J. W., 2119
 Scambia, G., 2359
 Scanni, A., 2087
 Scardino, P. T., 1267
 Scarpati, M. D. V., 63
 Schally, A., 1452
 Schauenstein, E., 511
 Schauenstein, K., 511
 Scheithauer, B. W., 502, 2564
 Scheithauer, W., 1646
 Schellhammer, P. F., 2164
 Schiessel, R., 1646
 Schild, S. E., 2564
 Schmid, C., 1432
 Schmid, H.-P., 1079
 Schnall, M. D., 2535
 Schneider, H. P. G., 2353
 Schnitt, S. J., 1426, 1921
 Schoder, M., 1646
 Scholnick, S. B., 1693
 Schomberg, P. J., 711
 Schover, L. R., 2229
 Schratter-Sehn, A. U., 1646
 Schroeder, G., 1888
 Schultz, P. N., 493
 Schutt, A. J., 1888
 Schwarting, R., 912
 Schwartz, G. K., 1988
 Schwartz, K. L., 1260
 Scopsi, L., 2173
 Scott, R. M., 864
 Scully, R. E., 927
 Sebo, T. J., 372
 Seiffert, J., 366
 Seiter, K., 1492
 Serizawa, A., 1671
 Serth, J., 1958
 Severson, R. K., 532, 1260
 Sevin, B.-U., 1438
 Shah, K. J., 858
 Sham, J. S. T., 202
 Shapiro, B., 2184
 Shapiro, C., 1756
 Sharifi, R., 2164
 Sharkey, R. M., 157
 Shekar, K. C., 2119
 Sheth, D. S., 745, 2136
 Shewach, D. S., 674
 Shibata, Y., 1677
 Shiina, H., 1762
 Shimada, M., 2094
 Shimamoto, Y., 396
 Shimosegawa, K., 422
 Shimosono, Y., 1229
 Shinkai, H., 1677
 Shiozawa, T., 1248
 Shirabe, K., 2094
 Shiraishi, M., 1794
 Shirakawa, H., 1762
 Shirakusa, T., 2346
 Siafakas, N., 441
 Sickles, E. A., 1395
 Siegel, J. A., 157
 Sigurdson, E. R., 2515
 Silver, B., 1426, 1921
 Simon, M. S., 1708
 Sinatra, M. A., 48
 Sindelar, W. F., 598
 Singnomklo, T., 968
 Sirijerachai, C., 1813
 Sisson, J. C., 2184
 Skingley, P., 1470
 Skipper, B. J., 1617
 Sklar, C., 1340
 Sklar, C. A., 1996
 Slatkin, N. E., 1899
 Slattery, M., 1629
 Slattery, M. L., 1666
 Slootweg, P. J., 991
 Small, E. J., 1775
 Smalley, S. R., 1789
 Smith, K. E., 1461
 Smyrk, T., 1149
 Snead, K., 152
 Sneige, N., 773
 Soares, J., 2300
 Solin, L. J., 2535
 Solomon, M., 2146
 Soloway, M. S., 2164
 Somma, L., 2087
 Sorkine, P., 1125
 Spaulding, S. A., 2184
 Speight, P. M., 1374
 Sperti, C., 237
 Spessa, E., 244
 Spies, S. M., 1861
 Spiridonidis, C. H., 2070
 Spiridonidis, C. H., 741
 Spitz, M. R., 1004
 Staerman, F., 1055
 Stain, S., 517
 Stampino, C. G., 2087
 Stanus, E., 1098
 Steele, G. D., Jr., 918
 Stein, A. S., 1899
 Steinberg, S. M., 901
 Steinschifter, W., 511
 Stewart, A. K., 1505
 Stoll, B. A., 2465
 Strang, P., 1942
 Stratis, M., 2146
 Straume, O., 1211
 Study Group on Cancer Survival in
 Developing Countries, 2461
 Su, C.-Y., 2063
 Su, I.-J., 1805
 Suarez, C. M., 1403
 Suehiro, Y., 1119
 Sugano, I., 695
 Sugarman, J. R., 1564
 Sugawara, T., 2313
 Sugihara, K., 1179, 1871
 Sugimachi, K., 1229, 1794, 2094
 Suguwara, K., 1187
 Sullivan, L. D., 480
 Suman, V., 711
 Suthipinhawong, C., 1813
 Sutton, D. M. S., 2153
 Suwanwela, N., 1813
 Suzuk, L., 704
 Suzuki, S., 1671
 Swalsky, P. A., 2288
 Swaminathan, R., 2461
 Swayne, L. C., 157

T

Tacy, N. J., 1461
 Tada, S., 1660
 Tada, T., 1929
 Tai, T., 43
 Tajima, Y., 695
 Takahashi, T., 403, 2199
 Takai, E., 1384
 Takayama, K., 416
 Takebayashi, Y., 226
 Takeda, T., 1049
 Takenaka, K., 2094
 Taketani, Y., 803, 1935
 Tamai, K., 1388
 Tamura, K., 1187
 Taraglio, S., 1195
 Tarbell, N. J., 864
 Tarpey, J., 1203
 Tassinari, D., 1477
 Tateno, H., 2313
 Taverna, M., 448
 Teichert, H.-M., 1452
 Tempfer, C., 273
 ten Bokkel Huinink, W. W., 118
 Tendi, E., 2366
 Tenney, M., 1527, 1533, 1574
 Teramoto, Y., 267
 Terek, R. M., 70
 Territo, M. C., 2421
 Terry, M. B., 723
 Testa, A., 1300
 Teufel, N. I., 1629
 Thamprasit, T., 1813
 Thompson, L. D., 2281
 Thompson, T. C., 1267
 Tien, H.-F., 1805
 Tinessa, V., 63
 Tisevich, D. A., 2620
 Tobioka, H., 461
 Tognazzi, K., 454
 Tokunaga, O., 396, 2101
 Tolar, B., 1308
 Tome, D., 1574
 Tomikawa, M., 1794
 Tominaga, T., 403
 Tonelli, F., 2400
 Tong, L., 1004
 Torchio, B., 1195
 Torchio, P., 1195
 Toth, K., 2427
 Toubanc, M., 1079
 Townsend, P., 1789
 Travis, W. D., 729
 Treat, M. R., 723
 Treseler, P. A., 834
 Trevisani, L., 1477
 Trias, I., 376
 Tribukait, B., 1942

Triller, J., 2318
 Trippoli, S., 2366
 Troncoso, P., 362
 Tropé, C. G., 433, 1740
 Troyan, S. L., 1921
 Tsai, M.-H., 1972
 Tsao, T.-Y., 24
 Tsark, J. A., 1582
 Tsark, J. A. U., 1558
 Tsatalpas, P., 2170
 Tseng, C.-J., 794
 Tsokos, M., 901
 Tsuji, M., 827
 Tsuji, T., 232
 Tsukamoto, K., 1929
 Tsunoda, S., 287
 Tsuruta, N., 416
 Tsuzuki, T., 287
 Tulpule, A., 517
 Turci, D., 2087
 Twardy, D. J., 1284
 Tyson, L. B., 2193

U

Uchitomi, Y., 1131
 Ueda, Y., 1388
 Uematsu, S., 232
 Ueo, H., 1229
 Uike, N., 1119
 Ulm, K., 487
 Umebara, Y., 133
 Urabe, Y., 232
 Urakami, S., 1762
 Utsugisawa, T., 422
 Užarević, B., 2543

V

Valanzano, R., 2400
 Valdivieso, M., 1851
 van de Rijn, M., 304
 van Gorp, J. M., 1220
 Vanhoefer, U., 2427
 van Mansfeld, A. D. M., 991
 Vasseur, B., 1686
 Vassilopoulou-Sellin, R., 493, 1043
 Vauthey, J.-N., 217
 Veltri, R., 372
 Venkatraman, E., 2193
 Venner, P. M., 2164
 Vergote, I. B., 1740
 Verstraeten, R. A., 118
 Vezeridis, M. P., 580
 Vicini, F. A., 948
 Vignati, S., 409
 Vilgrain, V., 1686
 Villena, V., 736
 Vitale, G., 1114
 Vitola, J. V., 2216

Vogelzang, N. J., 2164, 2411
 Voigt, L. F., 1417
 Vokes, E. E., 2411
 Volas, G. H., 267
 Volpe, R., 2400
 von Eschenbach, A. C., 324, 326, 372

W

Wade, J. L., 1085
 Wadler, S., 30
 Wakamatsu, K., 416
 Walter, A., 881
 Wanebo, H. J., 579, 580, 627, 688
 Wang, C.-C., 24
 Wang, C.-H., 1805, 1972
 Wang, H., 2340, 2421
 Wang, H.-M., 1972
 Wannakrairoj, P., 1813
 Warner, E., 2153
 Warnke, R. A., 304
 Watanabe, S., 852
 Waters, D., 362
 Wayne, J., 723
 Wazer, D. E., 1432
 Weaver-McClure, L., 901
 Weblacher, M., 511
 Weichselbaum, R. R., 1722
 Weiland, L. H., 2492
 Weinberg, D. S., 1756
 Weiss, N. S., 1417
 Weiss, R. B., 128
 Weiss, R. E., 2411
 Weiss, S., 2572
 Wells, H. B., 1587
 Wenig, B. M., 2281
 Werner, M., 1958
 Wexler, L. H., 901
 Wharton, J. T., 2229
 Wheeler, T. M., 366, 1267
 Whelan, R. L., 723
 White, E., 1417
 White, J. C., 751
 White, W. L., 383
 Widmark, A., 1066
 Wieand, H. S., 764
 Wiernik, P. H., 30, 2510
 Wiese, K. R., 1633
 Wiggins, C. L., 1533, 1569
 Wikler, D., 1098
 Wilkens, L. R., 1533
 Williamson, M. R., 1731
 Willshaw, H. E., 858
 Wilson-Lynch, K., 144
 Winchester, D. P., 101, 918, 1829, 1838, 2247
 Winkelmann, W., 892
 Wojno, K., 366
 Wold, L. E., 764

Wolf, T. A., 471
 Wolfert, R. L., 809
 Wolmark, N., 1403
 Womer, R. B., 1320
 Wong, R. M., 2502
 Wong, W. W., 2564
 Wood, B. L., 2223
 Woodward, M. L., 729
 Wound, D. B., 1527, 1533
 Wu, P. M., 202
 Wyman, B., 1722

X

Xing, P. X., 48
 Xu, H.-J., 17

Y

Yagi, H., 1762
 Yamada, K., 226
 Yamaguchi, T., 1388
 Yamaguchi, Y., 1892
 Yamamoto, A., 2199

Yamamoto, M., 133, 1794
 Yamamoto, T., 1049
 Yamashita, J.-I., 2346
 Yamashita, T., 2210
 Yamato, M., 1388
 Yamawaki, S., 1131
 Yang, F., 1461
 Yang, G., 1267
 Yano, T., 1384
 Yao, T., 1660
 Yarden, Y., 1272
 Yasko, A. W., 745, 2136
 Yasugi, T., 803
 Yasutomi, M., 403
 Yatsunami, J., 416
 Ying, Z., 157
 Yocom, K., 144
 Yokogi, H., 819
 Yokota, H., 803
 Yokoyama, H., 1384
 Yoneda, T., 1762
 Yoshida, K., 232
 Yoshida, Y., 1187
 Yoshikawa, H., 803, 1935

Yoshimoto, M., 1929
 Yoshioka, T., 1447
 Young, D. C., 2070
 Young, G. P., 48
 Yu, H., 2146
 Yuasa, Y., 2478

Z

Zach, M., 1646
 Zachrau, R. E., 778
 Zaloudek, C., 834
 Zamora, P., 211
 Zeltzer, L. K., 169
 Zempel, S. A., 2184
 Zetterberg, A., 1748
 Ziade, J., 1055
 Zimmer, M. A., 1861
 Zimmermann, A., 2318
 Zincke, H., 366
 Zino, P., 244
 Zins, M., 1686
 Zoli, M., 977

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 2, 1970: Section 3685. Title 39 United States Code) Date of Filing—October 1, 1996; Title of Publication—Cancer; Frequency of Issue—Twice Monthly; Annual Subscription Price—\$245.00; Location of Known Office of Publication—John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012; Location of Headquarters or General Business Offices of the Publisher—John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012; Publisher—John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012; Editor—Robert V. P. Hutter, M.D., 101 Old Short Hills Road, Suite 503, West Orange, NJ 07052-1023; Managing Editor—Diane Scott-Lichter, 101 Old Short Hills Road, Suite 503, West Orange, NJ 07052-1023; Owner—American Cancer Society, 1599 Clifton Road NE, Atlanta, GA 30329; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—none. A. Total no. copies printed (*net press run*), average 17,541, actual 17,457; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 13,085, actual 11,917; C. Total paid circulation, average 13,085, actual 11,917; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 376, actual 376; E. Total distribution (*sum of C and D*), average 13,461, actual 12,293; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 4080, actual 5164. Returns from news agents, none; G. Total (*sum of E and F—should equal net press runs shown in A*), average 17,541, actual 17,457. I certify that the statements made by me above are correct and complete. Susan Malawski, *Director, Subscription Fulfillment & Sales*.